

Terms & Conditions

Electronic Supporting Information files are available without a subscription to ACS Web Editions. The American Chemical Society holds a copyright ownership interest in any copyrightable Supporting Information. Files available from the ACS website may be downloaded for personal use only. Users are not otherwise permitted to reproduce, republish, redistribute, or sell any Supporting Information from the ACS website, either in whole or in part, in either machine-readable form or any other form without permission from the American Chemical Society. For permission to reproduce, republish and redistribute this material, requesters must process their own requests via the RightsLink permission system. Information about how to use the RightsLink permission system can be found at <http://pubs.acs.org/page/copyright/permissions.html>



ACS Publications

MOST TRUSTED. MOST CITED. MOST READ.

Copyright © 1998 American Chemical Society

Supplementary Experimental Results:

Wittig/Horner-Wadsworth-Emmons precursor PEG syntheses:

Fmoc-Gly-OPEG-OCH₃ (2):

Polyethylene glycol 5000 monomethyl ether (35.5g, 7.10 mmol), Fmoc-Gly (4.65g, 15.6 mmol, 2.2 eq) and PPh₃ (4.09g, 15.6 mmol, 2.2 eq) were dissolved in CH₂Cl₂ (400mL) and cooled to 0°C. Diethylazodicarboxylate (2.46mL, 15.6 mmol, 2.2 eq) was added dropwise over 30 min, and the reaction warmed to rt overnight. The reaction washed (2x H₂O, 1x satd NaCl), evaporated to dryness, taken up in acetone and reevaporated, dissolved in a minimum volume of DMF, and added to Et₂O (600 mL). The precipitated product was filtered, rinsed with cold EtOH and Et₂O, dried, then recrystallized from EtOH (400 mL).

¹H NMR (CDCl₃): δ 7.76 (d, J=7.3, 2H), 7.61 (d, J=7.6, 2H), 7.40 (t, J=7.4, 2H), 7.314 (t, J=7.6, 1H), 7.312 (t, J=7.6, 1H), 5.56 (t, J=10.0, 1H), 4.41 (d, J=6.9, 2H), 4.32 (m, 2H), 4.24 (t, J=7.1, 1H), 4.03 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG).

H₂N-Gly-OPEG-OCH₃:

Fmoc-Gly-OPEG-OCH₃ 2 (20.2g, 3.82 mmol) was dissolved in CH₂Cl₂ (50 mL) and piperidine (10 ml) was added. After 30 min the volume was reduced and the solution added to Et₂O (400 mL). The precipitated product was filtered, rinsed with cold EtOH and Et₂O, dried, then recrystallized from EtOH.

¹H NMR (CDCl₃): δ 4.29 (m, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG).

Fmoc-Ala-Gly-OPEG-OCH₃:

H₂N-Gly-OPEG-OCH₃ (20.1 g, 3.97 mmol), Fmoc-Ala (2.47g, 7.94 mmol, 2.0 eq), PyBOP (4.13g, 7.94 mmol, 2.0 eq), and HOBt.H₂O (1.22g, 7.94 mmol, 2.0 eq) were dissolved in DMF (50 mL) and DIPEA (1.94 mL, 11.1 mmol, 2.8 eq) was added. After 2h the reaction was poured into Et₂O (700ml), filtered, and worked up as usual.

¹H NMR (CDCl₃): δ 7.75 (d, J=7.3, 2H), 7.59 (d, J=6.9, 2H), 7.39 (t, J=7.2, 2H), 7.30 (t, J=7.4, 2H), 6.74 (br s, 1H), 5.54 (br d, J=7.3, 1H), 4.42 (d, J=6.5, 2H), 4.35-4.25 (m, 2H), 4.20 (t, J=6.7, 1H), 4.1-4.0 (m 1H), 3.8-3.45 (m, PEG), 3.37 (s, 3H, PEG), 1.40 (d, J=6.9, 3H).

H₂N-Ala-Gly-OPEG-OCH₃ (3):

Fmoc-Ala-Gly-OPEG-OCH₃ was deprotected as described earlier.

¹H NMR (CDCl₃): δ 7.84 (br s, 1H), 4.31-4.27 (m, 3H), 4.09 (dd, J=18.3,5.7, 1H, PEG), 4.04 (dd, J=18.3,5.3, 1H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 1.37 (d, J=6.9, 3H).

2-bromoethan-1-amide-Ala-Gly-OPEG-OCH₃ (5):

H₂N-Ala-Gly-OPEG-OCH₃ 3 (4.79g, 0.934 mmol) was dissolved in DMF (25 mL) and a solution of bromoacetic acid (0.290mL, 2.09 mmol, 2.2 eq) and diisopropylcarbodiimide (0.213mL, 2.09 mmol, 2.2 eq) in CH₂Cl₂ (5mL), preactivated for 10 min and filtered, was added. After 2.5 h the reaction was poured into Et₂O and worked up as usual.

¹H NMR (CDCl₃): δ 7.19 (d, J=7.2, 1H), 6.85 (t, J=5.2, 1H), 4.49 (quint, J=7.1, 1H), 4.34-4.24 (m, 2H), 4.08 (dd, J=17.9,5.7, 1H), 4.02 (dd, J=17.9,5.7, 1H), 3.90 (d, J=13.4, 1H), 3.87 (d, J=13.4, 1H), 3.8-3.45 (m, PEG), 3.37 (s, 3H, PEG), 1.42 (d, J=7.2, 3H).

4-bromobut-2E-enoic acid:

Ethyl 4-bromocrotonate (4.77 g, 24.7 mmol) was stirred with LiOH.H₂O (1.55g, 37.0 mmol, 1.5 eq) in H₂O (20 mL) and EtOH (10 mL) for 1 h. The solution was washed with EtOAc (2x) and acidified with 2N HCl in the presence of CH₂Cl₂. The organic phase was removed, dried (MgSO₄), and

evaporated to dryness. Purification by flash column chromatography (80g silica, 2:1 EtOAc:Hex) gave 2.14 g of product (52%) which was recrystallized from Et₂O/hexane.

TLC (2:1 EtOAc:hex): R_f = 0.63; ¹H NMR (CDCl₃): δ 11.5 (br s, 1H), 7.12 (dt, J=15.1, 7.3, 1H), 6.05 (dd, J=15.4, 1.3, 1H), 4.03 (dd, J=7.3, 1.3, 2H); ¹³C NMR (CDCl₃): δ 170.37, 144.04, 123.59, 28.63.

4-bromobut-2E-en-1-amide-Ala-Gly-OPEG-OCH₃ (8):

H₂N-Ala-Gly-OPEG-OCH₃ **3** (0.956g, 0.186 mmol) was dissolved in DMF (5 mL) and a solution of bromocrotonic acid (0.062g, 0.372 mmol, 2.0 eq) and diisopropylcarbodiimide (0.058mL, 0.372 mmol, 2.0 eq) in CH₂Cl₂ (2mL), preactivated for 10 min and filtered, was added. After reaction overnight the solution was poured into Et₂O and worked up as usual.

¹H NMR (CDCl₃): δ 7.16 (t, J=6.1, 1H), 6.92 (dt, J=15.3, 7.4, 1H), 6.84 (d, J=7.2, 1H), 6.12 (d, J=15.3, 1H), 4.59 (quint, J=7.2, 1H), 4.35-4.2 (m, 2H), 4.10 (dd, J=18.1, 5.9, 1H, PEG), 4.02 (d, J=7.2, 2H), 3.98 (dd, J=17.9, 5.3, 1H, PEG), 3.8-3.45 (m, PEG), 3.37 (s, 3H, PEG), 1.41 (d, J=6.9, 3H).

E-diethylphosphonocrotonic acid:

Methyl diethylphosphonocrotonate (0.540 g, 2.28 mmol) was stirred with LiOH.H₂O (0.162g, 3.87 mmol, 1.5 eq) in H₂O (10 mL) and EtOH (1 mL) for 1.5 h. The solution was washed with CH₂Cl₂ (2x) and acidified with 1N HCl in the presence of CH₂Cl₂. The organic phase was removed, dried (MgSO₄), and evaporated to give 0.365g (72%) of an oil which solidified upon standing.

¹H NMR (CDCl₃): δ 9.2 (vbr s, 1H), 6.94 (dq, J=15.6, 8.0, 1H), 5.96 (ddd, J=15.6, 5.0, 1.1, 1H), 4.2-4.1 (m, 4H), 2.79 (dd, J=23.3, 8.0, 2H), 1.33 (t, J=7.0, 6H).

Wittig/Horner-Wadsworth-Emmons Reaction Products - see General Procedure and Table 1 for reaction conditions:

2-buten-1-amide-Ala-Gly-OPEG-OCH₃ (7, R = CH₃):

E: ¹H NMR (CDCl₃): δ 7.56 (br s, 1H), 6.92 (d, J=7.2, 1H), 6.84 (dq, J=14.4, 6.9, 1H), 5.96 (dq, J=15.0, 1.2, 1H), 4.60 (quint, J=7.2, 1H), 4.30-4.24 (m, 2H), 4.04 (dd, J=17.4, 5.9, 1H, PEG), 3.97 (dd, J=17.9, 5.5, 1H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 1.84 (dd, J=6.9, 1.5, 3H), 1.42 (d, J=7.2, 3H).

Z: ¹H NMR (CDCl₃): δ 6.11 (dq, J=11.4, 7.2, 1H), 5.89 (br d, J=11.8, 1H), 2.10 (dd, J=7.2, 1.5, 3H), 1.405 (d, J=8.4, 3H).

5-phenyl-penta-2,4-dien-1-amide-Ala-Gly-OPEG-OCH₃ (7, R = CH=CH-Ph):

2E,4E: ¹H NMR (CDCl₃): δ 7.5-7.15 (m, 4H), 7.45 (d, J=7.6, 2H), 7.34 (t, J=7.4, 2H), 6.86 (m, 1H), 6.70 (d, J=6.5, 1H), 6.07 (d, J=14.9, 1H), 4.64 (quint, J=7.2, 1H), 4.30 (t, J=4.8, 1H), 4.25 (t, J=4.6, 1H), 4.10 (dd, J=17.9, 5.7, 1H, PEG), 3.99 (dd, J=18.1, 5.5, 1H, PEG), 3.8-3.45 (m, PEG), 3.37 (s, 3H, PEG), 1.44 (d, J=6.9, 3H).

2Z,4E: ¹H NMR (CDCl₃): δ 8.29 (dd, J=15.6, 11.4, 1H), 7.5-7.15 (m, 1H), 7.51 (d, J=7.6, 2H), 7.32 (t, J=7.6, 2H), 6.86 (m, 1H), 6.74 (d, J=15.6, 1H), 6.64 (d, J=6.9, 1H), 6.60 (t, J=11.2, 1H), 5.72 (d, J=11.1, 1H), 4.62 (quint, J=7.2, 1H), 4.32 (t, J=4.6, 1H), 4.23 (dd, J=5.5, 3.6, 1H), 4.11 (dd, J=17.9, 5.3, 1H, PEG), 4.01 (dd, J=17.9, 5.9, 1H, PEG), 3.8-3.45 (m, PEG), 3.37 (s, 3H, PEG), 1.44 (d, J=6.9, 3H).

hexa-2,4-dien-1-amide-Ala-Gly-OPEG-OCH₃ (7, R = CH=CH-CH₃):

Also prepared by coupling sorbic acid with H₂N-Ala-Gly-OPEG-OCH₃ using PyBOP/HOBt/NMM as described earlier.

2E,4E: ^1H NMR (CDCl_3): δ 7.18 (dd, $J=15.1, 10.5$, 1H), 7.12 (br s, 1H), 6.51 (d, $J=6.9$, 1H), 6.16 (dd, $J=15.8, 10.5$, 1H), 6.08 (dq, $J=15.1, 6.5$, 1H), 5.82 (d, $J=15.3$, 1H), 4.61 (quint, $J=7.1$, 1H), 4.35-4.2 (m, 2H), 4.15-3.95 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.37 (s, 3H, PEG), 1.40 (d, $J=6.9$, 3H).

2Z,4E: ^1H NMR (CDCl_3): δ 7.47 (dd, $J=16.4, 10.7$, 1H), 7.07 (br s, 1H), 6.46 (d, $J=7.6$, 1H), 6.39 (t, $J=11.2$, 1H), 5.99 (dq, $J=15.3, 6.9$, 1H), 5.53 (d, $J=11.4$, 1H), 4.57 (quint, $J=7.2$, 1H), 4.35-4.2 (m, 2H), 4.15-3.95 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.37 (s, 3H, PEG), 1.40 (d, $J=6.9$, 3H).

4-methyl-penta-2,4-dien-1-amide-Ala-Gly-OPEG-OCH₃ (7, R = C(CH₃)=CH₂):

2E,4E: ^1H NMR (CDCl_3): δ 7.28 (d, $J=14.9$, 1H), 7.07 (t, $J=4.6$, 1H), 6.57 (d, $J=7.2$, 1H), 5.92 (d, $J=15.3$, 1H), 5.31 (s, 1H), 5.28 (s, 1H), 4.62 (quint, $J=6.9$, 1H), 4.35-4.2 (m, 2H), 4.15-3.95 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 1.87 (s, 3H), 1.41 (d, $J=6.9$, 3H).

2Z,4E: ^1H NMR (CDCl_3): δ 6.84 (br s, 1H), 6.46 (d, $J=8.0$, 1H), 6.28 (d, $J=12.2$, 1H), 5.78 (d, $J=12.6$, 1H), 5.11 (s, 2H), 4.56 (quint, $J=6.9$, 1H), 4.35-4.2 (m, 2H), 4.15-3.95 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 1.92 (s, 3H), 1.41 (d, $J=6.9$, 3H).

STILLE REACTIONS:

Organostannanes 16 - Synthesized by General Procedure A, B, or C:

1-(tri-*n*-butylstannane)-2-phenylethene:

Method A crude product: *E:Z:gem* 91:5:5

after purification by distillation: *E:Z:gem* 90:10:0

E: TLC (hex): $R_f=0.75$; ^1H NMR (CDCl_3): δ 7.42 (d, $J=7.3$, 2H), 7.33 (t, $J=7.6$, 2H), 7.22 (t, $J=7.2$, 1H), 6.87 (m, 2H), 1.55 (m, 6H), 1.35 (sex, $J=7.3$, 6H), 0.97 (dd, $J=8.4$, 8.4, 6H), 0.91 (t, $J=7.4$, 9H). ^{13}C NMR: 146.08, 138.78, 129.28, 128.39, 127.44, 125.94, 29.17, 27.36, 13.75, 9.60.

Z: TLC (hex): $R_f=0.75$; ^1H NMR (CDCl_3): δ 7.63 (d, $J=13.7$, 1H), 7.42 (d, $J=7.3$, 2H), 7.33 (t, $J=7.6$, 2H), 7.22 (t, $J=7.2$, 1H), 6.20 (d, $J=13.7$, 1H), 1.55 (m, 6H), 1.35 (sex, $J=7.3$, 6H), 0.97 (dd, $J=8.4$, 8.4, 6H), 0.91 (t, $J=7.4$, 9H).

1-(tri-*n*-butylstannane)-1-phenylethene:

TLC (hex): $R_f=0.75$; ^1H NMR (CDCl_3): δ 7.42 (d, $J=7.3$, 2H), 7.33 (t, $J=7.6$, 2H), 7.22 (t, $J=7.2$, 1H), 6.20 (s, 1H), 6.13 (s, 1H), 1.55 (m, 6H), 1.35 (sex, $J=7.3$, 6H), 0.97 (dd, $J=8.4$, 8.4, 6H), 0.91 (t, $J=7.4$, 9H).

1-(tri-*n*-butylstannane)-3,3-dimethyl-2-butene:

Method A crude product: *E:Z:gem* 100:0:0

after purification by distillation: *E:Z:gem* 100:0:0

E: TLC (hex): $R_f=0.85$; ^1H NMR (CDCl_3): δ 5.95 (d, $J=19.5$, 1H), 5.76 (d, $J=19.5$, 1H), 1.49 (quint, $J=7.7$, 6H), 1.30 (sex, $J=7.3$, 6H), 1.00 (s, 9H), 0.89 (t, $J=7.4$, 9H), 0.86 (dd, $J=8.0$, 8.0, 6H). ^{13}C NMR: 159.94, 119.67, 35.95, 29.24, 29.17, 27.30, 13.77, 9.43.

1-bromo-1-decyne:

^1H NMR (CDCl_3): δ 2.20 (t, $J=7.2$, 2H), 1.50 (quint, $J=7.3$, 2H), 1.4-1.35 (m, 2H), 1.35-1.20 (m, 8H), 0.88 (t, $J=6.9$, 3H). ^{13}C NMR (CDCl_3): δ 80.30, 37.41, 31.84, 29.19, 29.08, 28.82, 28.32, 22.67, 19.66, 14.07.

1-(tri-*n*-butylstannane)-1-decene:

Method A crude product: *E:Z:gem* 75:24:12

Method B crude product: *E:Z:gem* 85:11:4

Method C crude product: *E:Z:gem* 0:100:0

after purification by distillation (of *E* only): *E:Z:gem* 86:9:5

E: TLC (hex): $R_f=0.82$; ^1H NMR (CDCl_3): δ 5.94 (dt, $J=19.1, 6.0$, 1H), 5.85 (d, $J=19.1$, 1H), 2.12 (q, $J=6.7$, 2H), 1.55-1.2 (m, 24H), 0.95-0.8 (m, 9H), 0.89 (t, $J=7.4$, 9H). ^{13}C NMR: 149.83, 126.86, 38.01, 31.78, 29.53, 29.41, 29.29, 29.20, 29.01, 27.36, 22.78, 14.15, 13.75, 9.42.

Z: TLC (hex): $R_f=0.82$; ^1H NMR (CDCl_3): δ 6.51 (dt, $J=12.2, 7.0$, 1H), 5.77 (d, $J=12.6$, 1H), 2.01 (q, $J=6.8$, 2H), 1.55-1.2 (m, 24H), 0.95-0.8 (m, 9H), 0.89 (t, $J=7.4$, 9H).

1-bromo-3-methoxy-1-propyne:

^1H NMR (CDCl_3): δ 4.13 (s, 2H), 3.39 (s, 3H). ^{13}C NMR (CDCl_3): δ 75.94, 60.49, 57.55, 45.97.

1-(tri-*n*-butylstannane)-3-methoxy-1-propene:

Method A crude product: *E:Z:gem* 60:22:18

Method B crude product: *E:Z:gem* 73:22:5

after purification by flash column chromatography (25:1 pent:Et₂O): *E:Z:gem* 92:5:3

E: TLC (20:1 pent:Et₂O): $R_f=0.20$; ^1H NMR (CDCl_3): δ 6.21 (dt, $J=19.1$, 1.2, 1H), 6.04 (dt, $J=19.1, 5.2$, 1H), 3.95 (dd, $J=5.2, 1.3$, 2H), 3.34 (s, 3H), 1.49 (quint, $J=7.7$, 6H), 1.30 (sex, $J=7.3$, 6H), 0.95-0.85 (m, 6H), 0.89 (t, $J=7.4$, 9H). ^{13}C NMR (CDCl_3): δ 144.35, 131.02, 76.24, 57.73, 29.05, 27.24, 13.63, 9.34.

Z: TLC (20:1 pent:Et₂O): $R_f=0.31$; ^1H NMR (CDCl_3): δ 6.61 (dt, $J=13.0, 5.3$, 1H), 6.08 (dt, $J=12.2, 1.1$, 1H), 3.90 (dd, $J=5.3, 1.5$, 2H), 3.33 (s, 3H), 1.49 (quint, $J=7.7$, 6H), 1.30 (sex, $J=7.3$, 6H), 0.95-0.85 (m, 6H), 0.89 (t, $J=7.4$, 9H). ^{13}C NMR (CDCl_3): δ 143.75, 131.48, 75.02, 57.90, 29.13, 27.35, 13.67, 10.69.

2-(tri-*n*-butylstannane)-3-methoxy-1-propene:

TLC (20:1 pent:Et₂O): $R_f=0.31$; ^1H NMR (CDCl_3): δ 5.85 (q, $J=1.9$, 1H), 5.26 (dt, $J=2.7$, 1.4, 1H), 4.02 (t, $J=1.5$, 2H), 3.30 (s, 3H), 1.55-1.45 (m, 6H), 1.35-1.25 (m, 6H), 0.95-0.85 (m, 6H), 0.89 (t, $J=7.4$, 9H). ^{13}C NMR (CDCl_3): δ 152.94, 124.53, 79.67, 57.65, 29.06, 27.31, 13.67, 9.50.

1-(tri-*n*-butylstannane)-3-hydroxy-1-propene:

Method A crude product: *E:Z:gem* 51:29:20

after purification by flash column chromatography (20:1 hex:EtOAc): *E:Z:gem* 99:1:0, 0:69:31

E: TLC (5:1 hex:EtOAc): $R_f=0.50$; ^1H NMR (CDCl_3): δ 6.22 (d, $J=19.1$, 1H), 6.16 (dt, $J=19.5, 3.8$, 1H), 4.18 (dt, $J=6.1, 3.8$, 2H), 1.49 (quint, $J=7.7$, 6H), 1.31 (sex, $J=7.3$, 6H), 0.95-0.85 (m, 6H), 0.89 (t, $J=7.2$, 9H). ^{13}C NMR (CDCl_3): δ 147.01, 127.95, 66.07, 29.00, 27.21, 13.59, 9.30.

Z: TLC (5:1 hex:EtOAc): $R_f=0.63$; ^1H NMR (CDCl_3): δ 6.68 (dt, $J=13.0, 6.1$, 1H), 6.07 (d, $J=13.0$, 1H), 4.11 (t, $J=5.3$, 2H), 1.49 (quint, $J=7.7$, 6H), 1.31 (sex, $J=7.3$, 6H), 0.95-0.85 (m, 6H), 0.89 (t, $J=7.2$, 9H). ^{13}C NMR (CDCl_3): δ 146.39, 130.96, 65.78, 29.10, 27.23, 13.59, 10.51.

2-(tri-*n*-butylstannane)-3-hydroxy-1-propene:

TLC (5:1 hex:EtOAc): $R_f=0.63$; ^1H NMR (CDCl_3): δ 5.88 (d, $J=1.9$, 1H), 5.24 (d, $J=1.9$, 1H), 4.28 (d, $J=5.7$, 2H), 1.49 (q, $J=7.7$, 6H), 1.31 (sex, $J=7.3$, 6H), 0.95-0.85 (m, 6H), 0.89 (t, $J=7.2$, 9H). ^{13}C NMR (CDCl_3): δ 154.45, 122.50, 69.12, 29.10, 27.30, 13.59, 9.34.

1-(tri-*n*-butylstannane)-3-(*N,N'*-dimethylamino)-1-propene:

Method A crude product: *E:Z:gem* 47:40:13

after purification by flash column chromatography (2:1 hex:EtOAc): *E:Z:gem* 93:7:0

E: TLC (1:1 hex:EtOAc): $R_f=0.12$; ^1H NMR (CDCl_3): δ 6.09 (d, $J=19.1$, 1H), 5.99 (dt, $J=19.1$, 5.8, 1H), 2.97 (br d, $J=5.7$, 2H), 2.23 (s, 6H), 1.49 (quint, $J=7.7$, 6H), 1.29 (sex, $J=7.3$, 6H),

0.88 (t, J=7.2, 15H). ^{13}C NMR (CDCl_3): δ 145.94, 131.24, 66.41, 45.05, 29.04, 27.18, 13.62, 9.32.

Z: TLC (1:1 hex:EtOAc): R_f =0.30 ; ^1H NMR (CDCl_3): δ 6.55 (dt, J=12.6,6.3, 1H), 6.01 (dd, J=12.6,0.7 1H), 2.90 (br d, J=6.1, 2H), 2.23 (s, 6H), 1.55-1.45 (m, 6H), 1.31 (sex, J=7.3, 6H), 0.95-0.85 (m, 6H), 0.89 (t, J=7.4, 9H). ^{13}C NMR (CDCl_3): δ 146.16, 131.05, 64.96, 45.33, 29.17, 27.32, 13.68, 10.39.

2-(tri-n-butylstannane)-3-(N,N'-dimethylamino)-1-propene:

TLC (1:1 hex:EtOAc): R_f =0.30 ; ^1H NMR (CDCl_3): δ 5.77 (m, 1H), 5.18 (m, 1H), 2.95 (br s, 2H), 2.12 (s, 6H), 1.55-1.45 (m, 6H), 1.31 (sex, J=7.3, 6H), 0.95-0.85 (m, 6H), 0.89 (t, J=7.4, 9H). ^{13}C NMR (CDCl_3): δ 155.92, 124.74, 69.96, 45.33, 29.17, 27.46, 13.68, 9.55.

1-(tri-n-butylstannane)-3-amino-1-propene:

Method A crude product: *E:Z*:gem 69:19:12

after purification by flash column chromatography (1:2 hex:EtOAc): *E:Z*:gem 99:1:0

E: TLC (1:2 hex:EtOAc): R_f =0.15 ; ^1H NMR (CDCl_3): δ 6.12 (dt, J=19.1,4.2, 1H), 6.05 (d, J=19.1, 1H), 3.34 (d, J=4.2, 2H), 1.48 (quint, J=7.7, 6H), 1.30 (sex, J=7.3, 6H), 1.24 (br s, 2H), 0.95-0.85 (m, 6H), 0.88 (t, J=7.2, 9H). ^{13}C NMR (CDCl_3): δ 149.28, 125.23, 47.18, 28.61, 26.80, 13.18, 8.86.

Z: TLC (1:2 hex:EtOAc): R_f =0.28 ; ^1H NMR (CDCl_3): δ 6.58 (dt, J=12.6,6.3, 1H), 5.89 (d, J=12.6, 1H), 3.24 (dd, J=6.3,1.0, 2H), 1.55-1.45 (m, 6H), 1.30 (sex, J=7.3, 6H), 1.10 (br s, 2H), 0.95-0.85 (m, 6H), 0.88 (t, J=7.2, 9H). ^{13}C NMR (CDCl_3): δ 148.93, 128.77, 47.34, 28.97, 27.08, 13.46, 10.35.

2-(tri-n-butylstannane)-3-amino-1-propene:

TLC (1:2 hex:EtOAc): R_f =0.28 ; ^1H NMR (CDCl_3): δ 5.80 (d, J=1.7, 1H), 5.17 (d, J=1.8, 1H), 3.45 (t, J=1.7, 2H), 1.55-1.45 (m, 6H), 1.31 (sex, J=7.4, 6H), 1.10 (br s, 2H), 0.95-0.85 (m, 6H), 0.90 (t, J=7.2, 9H). ^{13}C NMR (CDCl_3): δ 156.68, 121.91, 50.76, 28.97, 27.16, 13.36, 9.30.

N-(t-butyloxycarbonyl)-3-amino-1-propyne:

^1H NMR (CDCl_3): δ 4.74 (br s, 1H), 3.91 (br s, 2H), 2.21 (dd, J=2.9,2.1, 1H), 1.44 (s, 9H). ^{13}C NMR (CDCl_3): δ 155.15, 80.02, 79.51, 70.89, 29.99, 28.08.

N-(t-butyloxycarbonyl-1-(tri-n-butylstannane)-3-amino-1-propene:

Method A crude product: *E:Z*:gem 65:24:11

after purification by flash column chromatography (25:1 hex:EtOAc): *E:Z*:gem 98:0:2

E: TLC (10:1 hex:EtOAc): R_f =0.51; ^1H NMR (CDCl_3): δ 6.08 (dt, J=19.1,1.4, 1H), 5.95 (dt, J=19.1,4.7, 1H), 4.60 (br s, 1H), 3.79 (br s, 2H), 1.48 (quint, J=7.6, 6H), 1.45 (s, 9H), 1.30 (sex, J=7.3, 6H), 0.89 (t, J=7.2, 9H), 0.87 (dd, J=8.8,7.3, 6H). ^{13}C NMR (CDCl_3): δ 155.57, 144.21, 128.63, 78.91, 45.84, 28.92, 28.26, 27.15, 13.56, 9.26.

Z: TLC (10:1 hex:EtOAc): R_f =0.57; ^1H NMR (CDCl_3): δ 6.49 (dt, J=12.6,6.5, 1H), 6.02 (d, J=12.6, 1H), 4.45 (br s, 1H), 3.70 (br t, J=5.3, 2H), 1.55-1.45 (m, 6H), 1.45 (s, 9H), 1.30 (sex, J=7.3, 6H), 0.95-0.85 (m, 6H), 0.89 (t, J=7.2, 9H). ^{13}C NMR (CDCl_3): δ 155.41, 144.11, 132.18, 79.14, 45.81, 29.06, 28.31, 27.18, 13.59, 10.22.

N-(t-butyloxycarbonyl-2-(tri-n-butylstannane)-3-amino-1-propene:

TLC (10:1 hex:EtOAc): R_f =0.57; ^1H NMR (CDCl_3): δ 5.79 (q, J=1.9, 1H), 5.22 (q, J=1.9, 1H), 4.52 (br s, 1H), 3.89 (br d, J=5.7, 2H), 1.55-1.45 (m, 6H), 1.45 (s, 9H), 1.30 (sex, J=7.3, 6H), 0.95-0.85 (m, 6H), 0.89 (t, J=7.2, 9H). ^{13}C NMR (CDCl_3): δ 155.41, 151.54, 124.75, 79.14, 29.01, 28.31, 27.18, 13.59, 9.32.

methyl 3-(tri-*n*-butylstannane)-prop-2-en-1-oate:

Method A crude product: *E:Z:gem* 38:60:2

after purification by flash column chromatography (50:1 hex:EtOAc): *E:Z:gem* 92:6:2 and 1:99:0

E: TLC (10:1 hex:EtOAc): $R_f=0.62$; ^1H NMR (CDCl_3): δ 7.75 (d, $J=19.5$, 1H), 6.30 (d, $J=19.5$, 1H), 3.75 (s, 3H), 1.50 (quint, $J=7.7$, 2H), 1.30 (sex, $J=7.5$, 6H), 0.97 (dd, $J=9.0, 7.1$, 6H), 0.89 (t, $J=7.2$, 9H). ^{13}C NMR (CDCl_3): δ 164.97, 152.41, 135.82, 51.28, 28.85, 27.12, 13.50, 9.49.

Z: TLC (10:1 hex:EtOAc): $R_f=0.80$; ^1H NMR (CDCl_3): δ 7.16 (d, $J=13.0$, 1H), 6.73 (d, $J=13.0$, 1H), 3.75 (s, 3H), 1.49 (quint, $J=7.7$, 2H), 1.29 (sex, $J=7.4$, 6H), 0.97 (dd, $J=8.0, 8.0$, 6H), 0.88 (t, $J=7.2$, 9H). ^{13}C NMR (CDCl_3): δ 167.92, 157.32, 134.85, 51.44, 29.13, 27.32, 13.68, 10.96.

3-(tri-*n*-butylstannane)-prop-2-en-1-oic acid:

Methyl 3-(tri-*n*-butylstannane)-prop-2-en-1-oate (1.21 g of a 57:36:7 *E:Z:gem* mixture) was dissolved in MeOH (10 ml) and THF (10mL) and treated with LiOH.H₂O (0.271g, 6.46 mmol, 2.0 eq) in H₂O (15mL). After stirring for 48h the mixture was washed with hexane, then acidified with 1N HCl and extracted with EtOAc. The organic fraction was dried (MgSO₄) and evaporated to dryness to give 0.98g (84%) of a 66:34:0 *E:Z:gem* mixture. Purification by flash column chromatography (10:1 hex:EtOAc): *E:Z:gem* 99:1:0 and 4:96:0

E: TLC (5:1 hex:EtOAc): $R_f=0.21$; ^1H NMR (CDCl_3): δ 11.8 (v br s, 1H), 7.91 (d, $J=19.5$, 1H), 6.32 (d, $J=19.5$, 1H), 1.51 (quint, $J=7.7$, 2H), 1.31 (sex, $J=7.3$, 6H), 0.99 (t, $J=8.1$, 6H), 0.89 (t, $J=7.3$, 9H). ^{13}C NMR (CDCl_3): δ 169.97, 156.44, 135.75, 28.95, 27.24, 13.64, 9.67.

Z: TLC (5:1 hex:EtOAc): $R_f=0.42$; ^1H NMR (CDCl_3): δ 12.3 (v br s, 1H), 7.39 (d, $J=12.8$, 1H), 6.77 (d, $J=12.8$, 1H), 1.49 (quint, $J=7.7$, 2H), 1.29 (sex, $J=7.2$, 6H), 0.97 (dd, $J=8.5, 7.6$, 6H), 0.88 (t, $J=7.3$, 9H). ^{13}C NMR (CDCl_3): δ 173.12, 161.90, 134.65, 29.14, 27.34, 13.74, 11.16.

Stille Solid Phase Reactions: Preparation of Precursors

The Wang resin components were prepared under identical conditions as the PEG compounds, except for the initial coupling of Fmoc-Aca. All coupling reactions gave a negative Kaiser test.

3-bromoprop-2-en-1-oic acid:

Propiolic acid (2.09g, 29.8 mmol) and 48% HBr (4mL, 37 mmol HBr, 1.4 eq) were heated at 140°C for 3 hr. The product, which solidified on cooling, was dissolved in CHCl₃, washed with saturated NaCl, dried (MgSO₄), and evaporated to dryness to give 4.13 g (92%) of pure product, (*E:Z* 73:27). Recrystallization (CHCl₃) gave 1.67 g (37%) of very pure *E* product (*E:Z* >99.5:<0.5).

E: ^1H NMR (CDCl_3): δ 11.0 (vbr s, 1H), 7.76 (d, $J=14.1$, 1H), 6.54 (d, $J=14.1$, 1H).

Z: ^1H NMR (CDCl_3): δ 11.0 (vbr s, 1H), 7.17 (d, $J=8.5$, 1H), 6.67 (d, $J=8.5$, 1H).

3-bromo-2-methylprop-2-en-1-oic acid:

E: ^1H NMR (CDCl_3): δ 11.8 (vbr s, 1H), 7.71 (q, $J=1.3$, 1H), 2.02 (d, $J=1.6$, 1H); ^{13}C NMR (CDCl_3): δ 170.76, 133.37, 125.85, 15.21.

***E*-bromoacrylamide-Gly-OPEG-OCH₃ (14, R₁ = H, Xaa₂-Xaa₁ = Gly):**

H₂N-Gly-OPEG-OCH₃ 13 (3.2g, 0.63 mmol) was dissolved in DMF (15 mL) and a solution of bromoacrylic acid (0.189g, 1.25 mmol, 2.0 eq) and diisopropylcarbodiimide (0.247mL, 1.58 mmol, 2.5 eq) in CH₂Cl₂ (5mL), preactivated for 10 min and filtered, was added. After reaction overnight the solution was poured into Et₂O and worked up as usual.

^1H NMR (CDCl_3): δ 7.48 (d, $J=13.4$, 1H), 6.76 (br s, 1H), 6.62 (d, $J=13.4$, 1H), 4.29 (t, $J=4.8$, 2H, PEG), 4.10 (d, $J=5.3$, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG)

Fmoc-Aca-OH:

6-Aminocaproic acid (4.08g, 31.1 mmol) and Na₂CO₃ (3.63g, 34.2 mmol, 1.1 eq) were dissolved in H₂O (190mL) and added dropwise over 1h to a solution of Fmoc-OSucc (10.5g, 31.1 mmol, 1.0 eq) in 1,4-dioxane (150 mL) at 0°C. The solution was allowed to warm to rt, and after 4 h was washed with Et₂O (2x), then acidified with 2N HCl in the presence of EtOAc. The organic fraction was removed and the aqueous fraction extracted with EtOAc (2x). The organic fractions were combined, washed with saturated NaCl, dried (MgSO₄) and evaporated to give 10.7g (97%) of white solid. The product was recrystallized from EtOAc/hex.

¹H NMR (CDCl₃, 2 conformers, 75:25) major: δ 10.0 (vbr s, 1H), 7.76 (d, J=7.6, 2H), 7.59 (d, J=7.2, 2H), 7.40 (t, J=7.6, 2H), 7.31 (t, J=7.2, 2H), 4.78 (t, J=4.6, 1H), 4.40 (d, J=6.9, 2H), 4.21 (t, J=6.9, 1H), 3.20 (q, J=6.6, 2H), 2.36 (t, J=7.4, 2H), 1.66 (quint, J=7.6, 2H), 1.53 (quint, J=7.2, 2H), 1.37 (quint, J=7.6, 2H); minor: δ 10.0, (vbr s, 1H), 7.76 (d, J=7.6, 2H), 7.59 (d, J=7.2, 2H), 7.40 (t, J=7.6, 2H), 7.31 (t, J=7.2, 2H), 5.32 (br s, 1H), 4.46 (br m, 2H), 4.25 (br m, 1H), 3.06 (br m, 2H), 2.36 (t, J=7.4, 2H), 1.60 (br m, 2H), 1.35 (br m, 2H), 1.30 (br m, 2H).

¹H NMR (CD₃OD, 2 conformers, 85:15) major: δ 7.79 (d, J=7.2, 2H), 7.64 (d, J=7.2, 2H), 7.38 (t, J=7.4, 2H), 7.30 (t, J=7.4, 2H), 7.08 (br t, 1H), 4.34 (d, J=6.9, 2H), 4.19 (t, J=6.9, 1H), 3.10 (q, J=6.6, 2H), 2.29 (t, J=7.4, 2H), 1.61 (quint, J=7.5, 2H), 1.50 (quint, J=7.2, 2H), 1.35 (quint, J=7.6, 2H); minor: δ 7.79 (d, J=7.2, 2H), 7.64 (d, J=7.2, 2H), 7.38 (t, J=7.4, 2H), 7.30 (t, J=7.4, 2H), 6.46 (br s, 1H), 4.52 (br m, 2H), 4.22 (br m, 1H), 2.79 (br m, 2H), 2.24 (br m, 2H), 1.50 (br m, 2H), 1.25-1.05 (br m, 4H).

Fmoc-Aca-OPEG-OCH₃ (12, Xaa₁ = Aca):

Polyethylene glycol 5000 monomethyl ether (15.3g, 3.05 mmol) and DMAP (0.019g, 0.153 mmol, 0.05 eq) were dissolved in CH₂Cl₂ (50 mL) and a solution of Fmoc-Aca (2.16g, 6.10 mmol, 2.0 eq) and diisopropylcarbodiimide (0.955mL, 6.10 mmol, 2.0 eq) in CH₂Cl₂ (50mL), preactivated for 10 min and filtered, was added. After reaction overnight the solution was poured into Et₂O and worked up as usual.

¹H NMR (CDCl₃, 2 conformers, 80:20) major: δ 7.74 (d, J=7.6, 2H), 7.57 (d, J=7.3, 2H), 7.38 (t, J=7.4, 2H), 7.29 (t, J=7.4, 2H), 4.93 (t, J=5.5, 1H), 4.39 (d, J=6.9, 2H), 4.20 (m, 3H, PEG + CH), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.17 (q, J=6.7, 2H), 2.33 (t, J=7.4, 2H), 1.63 (quint, J=7.4, 2H), 1.50 (quint, J=7.2, 2H), 1.33 (quint, J=7.7, 2H); minor: δ 7.74 (d, J=7.6, 2H), 7.57 (d, J=7.3, 2H), 7.38 (t, J=7.4, 2H), 7.29 (t, J=7.4, 2H), 4.59 (br s, 1H), 4.40 (br m, 2H), 4.20 (m, 3H, PEG + CH), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.05 (br m, 2H), 2.33 (br m, 2H), 1.58 (br m, 2H), 1.3-1.2 (br m, 4H).

Fmoc-Aca-OWang (12, Xaa₁ = Aca):

Wang resin (Advanced Chemtech, 100-200 mesh, 0.85 mmol/g, 1.12g, 0.98 mmol), Fmoc-Aca (0.83g, 2.4 mmol, 2.4 eq) and PPh₃ (0.62, 2.4 mmol, 2.4 eq) in DMF (20mL) at 0°C were treated with diisopropylazodicarboxylate (0.465mL, 2.4 mmol, 2.4 eq). After reaction overnight the solvent was removed and the resin rinsed with DMF (3x) and CH₂Cl₂ (3x), then dried.

H₂N-Aca-OPEG-OCH₃:

Fmoc-Aca-OPEG-OCH₃ **12** was deprotected as described earlier.

¹H NMR (CDCl₃): δ 4.21 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 2.77 (t, J=6.9, 2H), 2.33 (t, J=7.2, 2H), 1.64 (quint, J=7.4, 2H), 1.55 (quint, J=7.2, 2H), 1.36 (quint, J=7.4, 2H).

Fmoc-Ala-Aca-OPEG-OCH₃ (Xaa₂-Xaa₁ = Ala-Aca):

H₂N-Gly-OPEG-OCH₃ (20.1 g, 3.97 mmol) was coupled with Fmoc-Ala using PyBOP/HOBt/DIPEA as described earlier.

¹H NMR (CDCl₃): δ 7.74 (d, J=7.6, 2H), 7.57 (d, J=7.6, 2H), 7.38 (t, J=7.4, 2H), 7.29 (t, J=7.4, 2H), 6.15 (br s, 1H), 5.46 (br d, J=7.3, 1H), 4.39 (d, J=6.9, 2H), 4.19 (m, 3H, PEG + CH), 4.15

(m, 1H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.23 (br q, J=6.0, 2H), 2.31 (t, J=7.4, 2H), 1.61 (br quint, J=7.5, 2H), 1.49 (br quint, J=7.2, 2H), 1.36 (d, J=6.5, 3H), 1.32 (br quint, J=7.7, 2H).

Fmoc-Arg(Pbf)-Aca-OPEG-OCH₃ (Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

H₂N-Gly-OPEG-OCH₃ (20.1 g, 3.97 mmol) was coupled with Fmoc-Arg(Pbf) using PyBOP/HOBt/DIPEA as described earlier.

¹H NMR (CDCl₃): δ 7.74 (d, J=7.6, 2H), 7.58 (d, J=7.2, 2H), 7.37 (t, J=7.4, 2H), 7.28 (t, J=7.2, 2H), 7.30 (br s, 1H), 6.78 (br s, 2H), 5.85 (br s, 1H), 5.80 (d, J=8.4, 1H), 4.35 (d, J=6.9, 2H), 4.40-4.30 (m, 1H), 4.25-5.15 (m, 1H), 4.19 (t, J=5.1, 3H, PEG) 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.35-3.30 (br m, 1H), 3.19 (m, 2H), 3.15-3.05 (br m, 1H), 2.92 (s, 2H), 2.61 (s, 3H), 2.53 (s, 3H), 2.33 (t, J=7.2, 2H), 2.07 (s, 3H), 1.80 (br m, 1H), 1.65-1.40 (m, 3H), 1.63 (br quint, J=7.4, 2H), 1.55 (br quint, J=7.1, 2H), 1.42 (s, 6H), 1.35 (br quint, J=7.8, 2H).

H₂N-Ala-Aca-OPEG-OCH₃ (13, Xaa₂-Xaa₁ = Ala-Aca):

Fmoc-Ala-Aca-OPEG-OCH₃ was deprotected as described earlier.

¹H NMR (CDCl₃): δ 7.40 (br s, 1H), 4.20 (m, 3H, PEG + CH), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.22 (br q, J=6.7, 2H), 2.32 (t, J=7.2, 2H), 1.63 (br quint, J=7.3, 2H), 1.52 (br quint, J=7.3, 2H), 1.35 (d, J=6.9, 3H), 1.35 (br quint, J=7.6, 2H).

H₂N-Arg(Pbf)-Aca-OPEG-OCH₃ (13, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

Fmoc-Arg(Pbf)-Aca-OPEG-OCH₃ was deprotected as described earlier.

¹H NMR (CDCl₃): δ 7.50 (br s, 1H), 6.26 (br s, 2H), 6.20 (br s, 1H), 4.20 (m, 3H, PEG + CH), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.30 (m, 1H), 3.22 (q, J=6.9, 2H), 3.15 (m, 1H), 2.94 (s, 2H), 2.58 (s, 3H), 2.51 (s, 3H), 2.32 (t, J=7.2, 2H), 2.07 (s, 3H), 1.80 (br m, 1H), 1.65-1.50 (m, 3H), 1.63 (br quint, J=7.4, 2H), 1.52 (br quint, J=7.3, 2H), 1.44 (s, 6H), 1.34 (br quint, J=7.6, 2H).

3-bromo-prop-2E-en-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (14, R¹ = H, Xaa₂-Xaa₁ = Ala-Aca):

H₂N-Arg(Pbf)-Aca-OPEG-OCH₃ 13 was coupled with 3-bromoprop-2-en-1-oic acid using DIC as described earlier.

¹H NMR (CDCl₃): δ 7.42 (d, J=13.4, 1H), 7.34 (br s, 1H), 6.93 (d, J=6.9, 1H), 6.60 (d, J=13.4, 1H), 6.30 (br s, 2H), 5.95 (br s, 1H), 4.62 (br s, 1H), 4.19 (t, J=4.6, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.1 (m, 4H), 2.94 (s, 2H), 2.61 (s, 3H), 2.53 (s, 3H), 2.32 (t, J=7.2, 2H), 2.08 (s, 3H), 1.9-1.8 (br m, 1H), 1.65-1.45 (m, 3H), 1.62 (br quint, J=7.2, 2H), 1.53 (br quint, J=7.4, 2H), 1.44 (s, 6H), 1.33 (br quint, J=7.3, 2H).

Stille Coupling Products on PEG resin (see Table 3 for reaction conditions and product purity)

penta-2E,4-diene-1-amide-Gly-OPEG-OCH₃ (17, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Gly):

¹H NMR (CDCl₃): δ 7.21 (dd, J=15.3, 11.1, 1H), 6.42 (dt, J=17.2, 10.5), 6.38 (br s, 1H), 5.96 (d, J=14.9, 1H), 5.55 (d, J=16.8, 1H), 5.42 (d, J=10.3, 1H), 4.29 (t, J=4.8, 2H, PEG), 4.14 (d, J=5.3, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG).

penta-2E,4-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.18 (dd, J=15.3, 11.1, 1H), 6.45-6.35 (m, 3H), 5.91 (d, J=14.9, 1H), 5.55 (d, J=17.2, 1H), 5.41 (d, J=10.3, 1H), 4.50 (quint, J=7.1, 1H), 4.20 (t, J=4.8, 2H, PEG), 3.8-3.45

(m, PEG), 3.36 (s, 3H, PEG), 3.22 (m, 2H), 2.31 (t, J=7.4, 2H), 1.61 (br quint, J=7.5, 2H), 1.49 (br quint, J=7.3, 2H), 1.37 (d, J=6.9, 3H), 1.33 (br quint, J=7.5, 2H).

penta-2E,4-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 7.14 (dd, J=15.1,11.2, 1H), 6.79 (d, J=8.0, 1H), 6.37 (dt, J=16.8, 10.4, 1H), 6.30 (br s, 2H), 5.99 (br s, 1H), 5.95 (d, J=15.3, 1H), 5.52 (d, J=17.2, 1H), 5.40 (d, J=9.9, 1H), 4.63 (br m, 1H), 4.19 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.26 (m, 2H), 3.19 (m, 2H), 2.94 (s, 2H), 2.60 (s, 3H), 2.52 (s, 3H), 2.31 (t, J=7.2, 2H), 2.07 (s, 3H), 1.85 (br m, 1H), 1.7-1.4 (m, 3H), 1.61 (br quint, J=7.4, 2H), 1.53 (br quint, J=7.2, 2H), 1.44 (s, 6H), 1.33 (br quint, J=7.4, 2H).

2-methylpenta-2E,4-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = Me, R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 6.87 (d, J=11.1, 1H), 6.60 (dt, J=16.4,10.7, 1H), 6.47 (d, J=6.9, 1H), 6.34 (t, J=4.8, 1H), 5.50 (d, J=16.8, 1H), 5.39 (d, J=10.3, 1H), 4.48 (quint, J=6.9, 1H), 4.20 (t, J=4.4, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.23 (q, J=6.5, 2H), 2.31 (t, J=7.2, 2H), 1.95 (s, 3H), 1.61 (br quint, J=7.3, 2H), 1.50 (br quint, J=7.3, 2H), 1.38 (d, J=6.9, 3H), 1.32 (br quint, J=7.6, 2H).

5-phenyl-penta-2E,4E-diene-1-amide-Gly-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = Ph, Xaa₂-Xaa₁ = Gly):

¹H NMR (CDCl₃): δ 7.44 (d, J=7.3, 2H), 7.33 (t, J=7.4, 2H), 7.45-7.25 (m, 2H), 6.85 (m, 2H), 6.47 (t, J=5.1, 1H), 6.06 (d, J=14.9, 1H), 4.30 (dd, J=5.5,4.0, 2H, PEG), 4.16 (d, J=5.3, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG).

5-phenyl-penta-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = Ph, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.43 (d, J=7.6, 2H), 7.37 (ddd, J=14.9, 7.4, 3.0, 1H), 7.33 (t, J=7.6, 2H), 7.28 (d, J=7.2, 1H), 6.85 (s, 1H), 6.84 (d, J=3.5, 1H), 6.44 (t, J=5.5, 1H), 6.39 (d, J=7.6), 6.00 (d, J=14.9, 1H), 4.52 (quint, J=7.1, 1H), 4.19 (t, J=4.8, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.22 (m, 2H), 2.31 (t, J=7.4, 2H), 1.62 (br quint, J=7.4, 2H), 1.50 (br quint, J=7.2, 2H), 1.39 (d, J=7.2, 3H), 1.33 (br quint, J=7.2, 2H).

5-phenyl-penta-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = Ph, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.42 (d, J=7.6), 7.35-7.25 (m, 1H), 7.32 (t, J=7.6, 2H), 7.27 (d, J=7.0, 1H), 6.84 (d, J=8.0), 6.81 (m, 2H), 6.31 (br s, 3H), 6.03 (d, J=14.9, 1H), 6.00 (br s, 1H), 4.64 (m, 1H), 4.18 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.15 (m, 4H), 2.93 (s, 2H), 2.61 (s, 3H), 2.53 (s, 3H), 2.31 (t, J=7.2, 2H), 2.08 (s, 3H), 1.9-1.8 (br m, 1H), 1.7-1.4 (m, 3H), 1.61 (br quint, J=7.5, 2H), 1.53 (br quint, J=7.4, 2H), 1.432 (s, 3H), 1.426 (s, 3H), 1.33 (br quint, J=7.5, 2H).

6,6-dimethyl-hepta-2E,4E-diene-1-amide-Gly-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = tBu, Xaa₂-Xaa₁ = Gly):

¹H NMR (CDCl₃):

EE δ 7.19 (dd, J=15.4,8.4, 1H), 6.24 (t, J=5.2, 1H), 6.06 (m, 2H), 5.85 (d, J=14.9, 1H), 4.29 (t, J=4.6, 2H, PEG), 4.13 (d, J=5.3, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG).

EZ δ 8.29 (dd, J=15.6,11.4, 1H), 6.59 (t, J=5.0, 1H), 6.48 (t, J=11.2, 1H), 6.13 (d, J=15.6, 1H), 5.97 (d, J=11.1, 1H), 4.29 (t, J=4.6, 2H, PEG), 4.13 (d, J=5.3, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG).

ZE δ 7.42 (dd, $J=15.4, 11.4$, 1H), 6.71 (t, $J=5.3$, 1H), 6.41 (t, $J=5.0$, 1H), 5.55 (d, $J=11.1$, 1H), 4.29 (t, $J=4.6$, 2H, PEG), 4.13 (d, $J=5.3$, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG).

6,6-dimethyl-hepta-2*E*,4*E*-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = *t*Bu, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.17 (dd, $J=14.9, 9.5$, 1H), 6.42 (br t, $J=5.1$, 1H), 6.22 (d, $J=7.6$, 1H), 6.07 (m, 2H), 5.79 (d, $J=14.9$, 1H), 4.49 (quint, $J=7.2$, 1H), 4.20 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.21 (br quint, $J=6.6$, 2H), 2.31 (br t, $J=7.4$, 2H), 1.61 (br quint, $J=7.5$, 2H), 1.49 (br quint, $J=7.2$, 2H), 1.36 (d, $J=6.9$, 3H), 1.32 (br quint, $J=7.2$, 2H), 1.04 (s, 9H).

6,6-dimethyl-hepta-2*E*,4*E*-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = *t*Bu, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 7.13 (dd, $J=14.9, 9.5$), 6.63 (br d, $J=8.0$, 1H), 6.36 (br s, 1H), 6.28 (br s, 2H), 6.04 (m, 2H), 5.84 (d, $J=15.3$, 1H), 4.61 (br m, 1H), 4.19 (br m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.1 (m, 4H), 2.94 (s, 2H), 2.60 (s, 3H), 2.52 (s, 3H), 2.31 (br t, $J=7.4$, 2H), 2.07 (s, 3H), 1.84 (br m, 1H), 1.65-1.4 (m, 3H), 1.61 (br quint, $J=7.3$, 2H), 1.52 (br quint, $J=7.1$, 2H), 1.44 (s, 6H), 1.32 (br quint, $J=7.0$, 2H), 1.03 (s, 9H).

trideca-2*E*,4*E*-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = (CH₂)₇CH₃, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.17 (dd, $J=15.1, 10.2$, 1H), 6.40 (t, $J=5.7$, 1H), 6.22 (d, $J=7.2$, 1H), 6.12 (dd, $J=15.1, 9.7$, 1H), 6.06 (dt, $J=15.3, 6.9$, 1H), 4.49 (quint, $J=7.2$, 1H), 4.20 (dd, $J=5.3, 4.2$, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.21 (q, $J=6.6$, 2H), 2.31 (t, $J=7.4$, 2H), 2.13 (q, $J=7.4$, 2H), 1.61 (br quint, $J=7.5$, 2H), 1.49 (br quint, $J=7.3$, 2H), 1.45-1.2 (m, 14H), 1.36 (d, $J=6.9$, 3H), 0.86 (t, $J=7.1$, 3H).

trideca-2*E*,4*E*-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = (CH₂)₇CH₃, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 7.12 (dd, $J=15.1, 9.7$, 1H), 6.66 (d, $J=8.0$, 1H), 6.29 (br s, 2H), 6.1-5.9 (m, 3H), 5.80 (d, $J=14.9$, 1H), 4.61 (br m, 1H), 4.19 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.15 (m, 4H), 2.94 (s, 2H), 2.60 (s, 3H), 2.52 (s, 3H), 2.31 (t, $J=7.4$, 2H), 2.12 (q, $J=7.4$, 2H), 2.08 (s, 3H), 1.84 (br m, 1H), 1.65-1.2 (m, 17H), 1.61 (br quint, $J=7.4$, 2H), 1.53 (br quint, $J=7.2$, 2H), 1.44 (s, 6H), 0.86 (t, $J=6.9$, 3H).

3-(2'-furan)-prop-2*E*ene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R³ = H, R² = R⁴ = -OCH=CH-, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.42 (s, 1H), 7.36 (d, $J=15.6$, 1H), 6.54 (d, $J=3.1$, 1H), 6.50-6.40 (m, 3H), 4.53 (quint, $J=7.0$, 1H), 4.19 (t, $J=4.6$, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.22 (m, 2H), 2.30 (t, $J=7.4$, 2H), 1.61 (br quint, $J=7.4$, 2H), 1.50 (br quint, $J=7.2$, 2H), 1.39 (d, $J=6.9$, 3H), 1.32 (br quint, $J=7.5$, 2H).

3-(2'-furan)-prop-2*E*ene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R³ = H, R² = R⁴ = -OCH=CH-, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.42 (s, 1H), 7.33 (d, $J=15.6$, 1H), 7.30 (br s, 1H), 6.83 (d, $J=8.0$, 1H), 6.51 (d, $J=3.0$, 1H), 6.42 (t, $J=2.5$, 1H), 6.39 (d, $J=15.3$, 1H), 6.28 (br s, 2H), 6.00 (br s, 1H), 4.66 (br m, 1H), 4.19 (br s, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.30-3.15 (m, 4H), 2.93 (s, 2H), 2.61 (s, 3H), 2.53 (s, 3H), 2.31 (t, $J=7.2$, 2H), 2.07 (s, 3H), 1.86 (br m, 1H), 1.7-1.4 (m, 3H), 1.61 (br quint, $J=7.4$, 2H), 1.53 (br quint, $J=6.9$, 2H), 1.43 (s, 6H), 1.33 (br quint, $J=7.4$, 2H).

3-(2'-thiophene)-prop-2Eene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R³ = H, R² = R⁴ = -SCH=CH-, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.71 (d, J=15.6, 1H), 7.30 (d, J=5.0, 1H), 7.20 (d, J=3.0, 1H), 7.02 (t, J=4.4, 1H), 6.55-6.45 (m, 2H), 6.27 (d, J=15.3, 1H), 4.54 (quint, J=7.1, 1H), 4.19 (br t, J=4.6, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.23 (m, 2H), 2.31 (t, J=7.4, 2H), 1.62 (br quint, J=7.4, 2H), 1.50 (br quint, J=7.2, 2H), 1.39 (d, J=6.9, 3H), 1.33 (br quint, J=7.6, 2H).

3-(2'-thiophene)-prop-2Eene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R³ = H, R² = R⁴ = -SCH=CH-, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.67 (d, J=15.3, 1H), 7.30 (d, J=5.0, 1H), 7.30 (br s, 1H), 7.17 (d, J=3.4, 1H), 7.01 (t, J=4.2, 1H), 6.83 (d, J=8.0, 1H), 6.34 (d, J=15.3, 1H), 6.28 (br s, 2H), 5.99 (br s, 1H), 4.67 (br m, 1H), 4.19 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.30-3.15 (m, 4H), 2.93 (s, 2H), 2.62 (s, 3H), 2.54 (s, 3H), 2.32 (t, J=7.4, 2H), 2.08 (s, 3H), 1.87 (br m, 1H), 1.7-1.4 (m, 3H), 1.62 (br quint, J=7.5, 2H), 1.54 (br quint, J=7.2, 2H), 1.44 (s, 6H), 1.34 (br quint, J=7.5, 2H).

6-hydroxy-hexa-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂OH, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.21 (dd, J=15.3,11.1, 1H), 6.49 (t, J=5.3, 1H), 6.43 (d, J=7.6, 1H), 6.38 (dd, J=15.3,11.1, 1H), 6.18 (dt, J=14.9,4.8, 1H), 5.90 (d, J=14.9, 1H), 4.50 (quint, J=7.1, 1H), 4.20 (t, J=4.6, 2H, PEG), 4.25 (t, J=4.8, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.24 (dt, J=13.4,6.6, 1H), 3.19 (dt, J=13.0,6.4, 1H), 2.30 (t, J=7.2, 2H), 2.23 (t, J=5.7, 1H), 1.61 (br quint, J=7.5, 2H), 1.49 (br quint, J=7.3, 2H), 1.37 (d, J=6.9, 3H), 1.31 (br quint, J=7.6, 2H).

6-hydroxy-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂OH, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 7.17 (dd, J=14.9,11.1, 1H), 6.87 (br m, 3H), 6.86 (d, J=7.6, 1H), 6.15 (dt, J=15.3,4.8, 1H), 6.00 (br s, 1H), 5.91 (d, J=15.3, 1H), 4.62 (br m, 1H), 4.19 (m, 2H, PEG), 4.24 (br m, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.15 (m, 4H), 2.94 (s, 2H), 2.60 (s, 3H), 2.52 (s, 3H), 2.31 (t, J=7.4, 2H), 2.08 (s, 3H), 1.85 (br m, 1H), 1.7-1.45 (m, 3H), 1.61 (br quint, J=7.5, 2H), 1.53 (br quint, J=7.0, 2H), 1.44 (s, 6H), 1.33 (br quint, J=7.2, 2H).

6-hydroxy-hexa-2E,4Zdiene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R⁴ = H, R³ = CH₂OH, Xaa₂-Xaa₁ = Ala-Aca):

mixture 80:20 Z:gem:

¹H NMR (CDCl₃): δ 7.50 (dd, J=14.7,12.0, 1H), 6.48 (m, 2H), 6.15 (t, J=11.4, 1H), 5.93 (dt, J=10.7,6.6, 1H), 5.92 (d, J=14.9, 1H), 4.50 (quint, J=7.2, 1H), 4.41 (m, 2H), 4.20 (t, J=4.8, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.15 (m, 2H), 2.31 (t, J=7.4, 2H), 2.23 (t, J=5.3, 1H), 1.61 (br quint, J=7.4, 2H), 1.49 (br quint, J=7.2, 2H), 1.37 (d, J=6.9, 3H), 1.31 (br quint, J=7.6, 2H).

4-hydroxymethyl-penta-2E,4-diene-1-amide-Ala-Aca-OPEG-OCH₃:

¹H NMR (CDCl₃): δ 6.08 (d, J=15.6, 1H), 5.56 (s, 1H), 5.45 (s, 1H), 4.30 (d, J=5.3, 1H).

6-methoxy-hexa-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂OCH₃, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.20 (dd, J=15.3,11.1, 1H), 6.45-6.30 (m, 3H), 6.09 (dt, J=15.3,5.3, 1H), 5.88 (d, J=14.9, 1H), 4.49 (quint, J=7.1, 1H), 4.20 (t, J=4.8, 2H, PEG), 4.01 (d, J=5.0, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.22 (q, J=7.1, 2H), 2.31 (t, J=7.4, 2H), 1.61 (br quint, J=7.5, 2H), 1.49 (br quint, J=7.3, 2H), 1.37 (d, J=6.9, 3H), 1.32 (br quint, J=7.6, 2H).

6-methoxy-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂OCH₃, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 7.16 (dd, J=14.9,11.1, 1H), 6.71 (d, J=7.6, 1H), 6.35-6.25 (br m, 3H), 6.06 (dt, J=15.6,5.4, 1H), 5.98 (br s, 1H), 5.92 (d, J=14.9, 1H), 4.63 (br m, 1H), 4.19 (m, 2H, PEG), 4.01 (d, J=5.3, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.35-3.15 (m, 4H), 2.94 (s, 2H), 2.61 (s, 3H), 2.53 (s, 3H), 2.32 (t, J=7.2, 2H), 2.08 (s, 3H), 1.84 (br m, 1H), 1.65-1.45 (m, 3H), 1.62 (br quint, J=7.3, 2H), 1.54 (br quint, J=7.5, 2H), 1.44 (s, 6H), 1.33 (br quint, J=7.6, 2H).

6-amino-hexa-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂NH₂, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.21 (dd, J=15.1,10.9, 1H), 6.39 (t, J=4.8, 1H), 6.30 (d, J=6.9, 1H), 6.27 (dd, J=15.3,11.1, 1H), 6.16 (dt, J=15.3,5.5, 1H), 5.85 (d, J=14.9, 1H), 4.50 (quint, J=7.1, 1H), 4.20 (t, J=4.6, 2H, PEG), 3.8-3.45 (m, PEG + 2H), 3.36 (s, 3H, PEG), 3.22 (m, 2H), 2.31 (t, J=7.2, 2H), 1.61 (br quint, J=7.3, 2H), 1.50 (br quint, J=7.2, 2H), 1.37 (d, J=6.9, 3H), 1.32 (br quint, J=7.3, 2H).

6-amino-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂NH₂, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 7.17 (dd, J=14.7,10.9, 1H), 6.76 (d, J=6.5, 1H), 6.30 (br s, 2H), 6.23 (dd, J=14.1,11.8, 1H), 6.13 (dt, J=15.3,4.9, 1H), 6.06 (br s, 1H), 5.89 (d, J=15.1, 1H), 4.62 (br m, 1H), 4.19 (br m, 2H, PEG), 3.8-3.45 (m, PEG + 2H), 3.36 (s, 3H, PEG), 3.35-3.1 (br m, 4H), 2.94 (s, 2H), 2.61 (s, 3H), 2.53 (s, 3H), 2.32 (t, J=7.4, 2H), 2.08 (s, 3H), 1.84 (br m, 1H), 1.7-1.4 (m, 3H), 1.62 (br quint, J=7.2, 2H), 1.53 (br quint, J=6.8, 2H), 1.44 (s, 6H), 1.33 (br quint, J=7.0, 2H).

N-(t-butyloxycarbonyl)-6-amino-hexa-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂NHBoc, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.18 (dd, J=14.9,11.1, 1H), 6.39 (br t, J=5.5, 1H), 6.32 (d, J=7.2, 1H), 6.24 (dd, J=15.3,11.1, 1H), 6.02 (dt, J=15.3,5.7, 1H), 5.86 (d, J=15.3, 1H), 4.49 (quint, J=7.2, 1H), 4.75 (br s, 1H), 4.20 (t, J=4.8, 2H, PEG), 3.84 (br m, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.22 (m, 2H), 2.31 (t, J=7.4, 2H), 1.61 (br quint, J=7.4, 2H), 1.49 (br quint, J=7.3, 2H), 1.43 (s, 9H), 1.37 (d, J=6.9, 3H), 1.32 (br quint, J=7.6, 2H).

N-(t-butyloxycarbonyl)-6-amino-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂NHBoc, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 7.13 (dd, J=14.9,11.1, 1H), 6.74 (d, J=8.0, 1H), 6.28 (br s, 2H), 6.19 (dd, J=15.1,11.2, 1H), 6.00 (br s, 1H), 5.99 (dt, J=14.9,5.7, 1H), 5.89 (d, J=14.9, 1H), 4.78 (br s, 1H), 4.62 (br m, 1H), 4.19 (m, 2H, PEG), 3.83 (br m, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.1 (m, 4H), 2.93 (s, 2H), 2.60 (s, 3H), 2.52 (s, 3H), 2.31 (t, J=7.4, 2H), 2.08 (s, 3H), 1.84 (br m, 1H), 1.7-1.45 (m, 3H), 1.61 (br quint, J=7.4, 2H), 1.53 (br quint, J=7.3, 2H), 1.44 (s, 6H), 1.43 (s, 9H), 1.33 (br quint, J=7.5, 2H).

N-(t-butyloxycarbonyl)-6-amino-2-methylhexa-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = Me, R² = R³ = H, R⁴ = CH₂NHBoc, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 6.89 (d, J=10.7, 1H), 6.43 (br s, 1H), 6.40 (dd, J=13.9,11.2, 1H), 6.32 (br s, 1H), 5.96 (dt, J=15.3,5.9, 1H), 4.48 (quint, J=7.0, 1H), 4.73 (br s, 1H), 4.20 (t, J=4.6, 2H, PEG), 3.84 (br s, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.23 (q, J=6.5, 2H), 2.31 (t, J=7.2, 2H), 1.94 (s, 3H), 1.61 (br quint, J=7.4, 2H), 1.50 (br quint, J=7.3, 2H), 1.44 (s, 9H), 1.38 (d, J=6.9, 3H), 1.32 (br quint, J=7.6, 2H).

(N,N'-dimethyl)-6-amino-hexa-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.20 (dd, J=15.3,11.1, 1H), 6.39 (br t, J=5.3, 1H), 6.31 (d, J=7.6, 1H), 6.25 (dd, J=15.1,10.9, 1H), 6.07 (dt, J=15.3,6.5, 1H), 5.84 (d, J=14.9, 1H), 4.49 (quint, J=7.2, 1H), 4.20 (t, J=4.8, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.21 (q, J=6.6, 2H), 2.99 (d, J=6.5, 2H), 2.21 (s, 6H), 2.31 (t, J=7.2, 2H), 1.61 (br quint, J=7.5, 2H), 1.49 (br quint, J=7.3, 2H), 1.36 (d, J=6.9, 3H), 1.31 (br quint, J=7.6, 2H).

(N,N'-dimethyl)-6-amino-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 7.16 (dd, J=15.2,10.9, 1H), 6.70 (d, J=8.0, 1H), 6.29 (br s, 2H), 6.23 (dd, J=15.3,10.7, 1H), 6.05 (dt, J=15.3,7.0, 1H), 6.00 (br s, 1H), 5.89 (d, J=15.3, 1H), 4.63 (br m, 1H), 4.19 (m, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.1 (m, 4H), 2.99 (d, J=6.5, 2H), 2.94 (s, 2H), 2.60 (s, 3H), 2.53 (s, 3H), 2.31 (t, J=7.4, 2H), 2.21 (s, 6H), 2.07 (s, 3H), 1.84 (br m, 1H), 1.65-1.45 (m, 3H), 1.61 (br quint, J=7.4, 2H), 1.53 (br quint, J=7.3, 2H), 1.44 (s, 6H), 1.33 (br quint, J=7.6, 2H).

5-carboxy-penta-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CO₂H, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.35-7.20 (m, 2H), 6.92 (br s, 1H), 6.52 (br s, 1H), 6.27 (br d, J=14.1, 1H), 6.17 (br d, J=14.1, 1H), 4.51 (quint, J=7.2, 1H), 4.20 (t, J=4.6, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.3-3.15 (m, 2H), 2.31 (t, J=7.2, 2H), 1.61 (br quint, J=7.4, 2H), 1.50 (br quint, J=7.2, 2H), 1.38 (d, J=6.9, 3H), 1.33 (br quint, J=7.6, 2H).

5-carboxy-penta-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CO₂H, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.45 (br s, 1H), 7.4-7.15 (m, 2H), 6.35 (br d, J=14.1, 1H), 6.34 (br s, 3H), 6.15 (br d, J=13.7, 1H), 6.02 (vbr s, 1H), 4.70 (br s, 1H), 4.19 (br s, 2H, PEG), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.35-3.1 (m, 4H), 2.94 (s, 2H), 2.62 (s, 3H), 2.53 (s, 3H), 2.32 (t, J=7.2, 2H), 2.08 (s, 3H), 1.85 (br s, 1H), 1.7-1.45 (m, 3H), 1.61 (br quint, J=7.5, 2H), 1.53 (br s, 2H), 1.44 (s, 6H), 1.33 (br m, 2H).

5-carboxymethyl-penta-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CO₂CH₃, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 7.35-7.20 (m, 2H), 6.66 (d, J=7.2, 1H), 6.36 (t, J=5.5, 1H), 6.23 (d, J=14.1, 1H), 6.16 (d, J=14.5, 1H), 4.49 (quint, J=7.1, 1H), 4.20 (t, J=4.8, 2H, PEG), 3.8-3.45 (m, PEG + 3H), 3.36 (s, 3H, PEG), 3.22 (m, 2H), 2.31 (t, J=7.2, 2H), 1.61 (br quint, J=7.4, 2H), 1.50 (br quint, J=7.3, 2H), 1.38 (d, J=7.2, 3H), 1.32 (br quint, J=7.6, 2H).

5-carboxymethyl-penta-2E,4Zdiene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R² = R⁴ = H, R³ = CO₂CH₃, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 8.24 (dd, J=15.1,11.6, 1H), 6.61 (t, J=11.4, 1H), 6.55 (d, J=7.2, 1H), 6.39 (t, J=4.2, 1H), 6.14 (d, J=15.3, 1H), 5.91 (d, J=11.1, 1H), 4.51 (quint, J=7.2, 1H), 4.20 (m, 2H, PEG), 3.8-3.45 (m, PEG + 3H), 3.36 (s, 3H, PEG), 3.3-3.2 (m, 2H), 2.31 (t, J=7.2, 2H), 1.62 (br quint, J=7.2, 2H), 1.50 (br quint, J=6.9, 2H), 1.38 (d, J=6.9, 3H), 1.32 (m, 2H).

5-carboxymethyl-penta-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R² = R³ = H, R⁴ = CO₂CH₃, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.37 (br s, 1H), 7.35-7.15 (m, 2H), 6.93 (d, J=7.6, 1H), 6.28 (br s, 2H), 6.28 (d, J=15.3, 1H), 6.13 (d, J=14.1, 1H), 5.94 (br s, 1H), 4.68 (br s, 1H), 4.19 (br s, 2H, PEG), 3.8-3.45 (m, PEG + 3H), 3.36 (s, 3H, PEG), 3.35-3.1 (m, 4H), 2.94 (s, 2H), 2.61 (s, 3H), 2.53

(s, 3H), 2.32 (t, J=7.1, 2H), 2.08 (s, 3H), 1.86 (br m, 1H), 1.7-1.4 (m, 3H), 1.62 (br quint, J=7.5, 2H), 1.54 (br quint, J=6.8, 2H), 1.44 (s, 6H), 1.33 (br quint, J=7.4, 2H).

4-ethoxy-penta-2E,4E-diene-1-amide-Gly-OPEG-OCH₃ (17, R¹ = R³ = R⁴ = H, R² = OEt, Xaa₂-Xaa₁ = Gly):

¹H NMR (CDCl₃): δ 7.00 (d, J=15.3, 1H), 6.33 (t, J=5.0, 1H), 6.28 (d, J=15.3, 1H), 4.40 (m, 2H), 4.29 (t, J=4.8, 2H, PEG), 4.14 (d, J=5.3, 2H), 3.81 (q, J=7.0, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 1.34 (t, J=6.9, 3H).

4-ethoxypenta-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = R³ = R⁴ = H, R² = OEt, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 6.97 (d, J=15.3, 1H), 6.40 (t, J=5.0, 1H), 6.35 (d, J=7.6, 1H), 6.25 (d, J=14.9, 1H), 4.50 (quint, J=7.2, 1H), 4.40 (s, 2H), 4.20 (t, J=4.6, 2H, PEG), 3.81 (q, J=7.0, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.22 (m, 2H), 2.31 (t, J=7.2, 2H), 1.61 (br quint, J=7.5, 2H), 1.49 (br quint, J=7.3, 2H), 1.37 (d, J=6.9, 3H), 1.35-1.28 (m, 2H), 1.34 (t, J=6.9, 3H).

4-ethoxypenta-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OPEG-OCH₃ (17, R¹ = R³ = R⁴ = H, R² = OEt, Xaa₂-Xaa₁ = Arg(Pbf)-Aca):

¹H NMR (CDCl₃): δ 7.30 (br s, 1H), 6.93 (d, J=15.2, 1H), 6.68 (br d, J=7.6, 1H), 6.31 (d, J=14.8, 1H), 6.26 (br s, 2H), 4.98 (br s, 1H), 4.65 (br m, 1H), 4.38 (s, 2H), 4.19 (m, 2H, PEG), 3.80 (q, J=7.0, 2H), 3.8-3.45 (m, PEG), 3.36 (s, 3H, PEG), 3.26 (m, 2H), 3.19 (m, 2H), 2.94 (s, 2H), 2.61 (s, 3H), 2.53 (s, 3H), 2.32 (t, J=7.4, 2H), 2.07 (s, 3H), 1.84 (br m, 1H), 1.7-1.4 (m, 3H), 1.61 (br quint, J=7.3, 2H), 1.53 (br quint, J=7.0, 2H), 1.44 (s, 6H), 1.4-1.3 (m, 2H), 1.33 (t, J=6.9, 3H).

4-ethoxy-2-methyl-penta-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (17, R¹ = Me, R² = OEt, R³ = R⁴ = H, Xaa₂-Xaa₁ = Ala-Aca):

¹H NMR (CDCl₃): δ 6.63 (s, 1H), 6.45 (d, J=7.2, 1H), 6.31 (t, J=5.0, 1H), 4.46 (quint, J=7.1, 1H), 4.34 (s, 1H), 4.30 (d, J=1.5, 1H), 4.20 (t, J=4.8, 2H, PEG), 3.8-3.45 (m, PEG + 2H), 3.36 (s, 3H, PEG), 3.23 (q, J=6.7, 2H), 2.31 (t, J=7.2, 2H), 2.15 (s, 3H), 1.62 (br quint, J=7.5, 2H), 1.50 (br quint, J=7.2, 2H), 1.38 (d, J=6.9, 3H), 1.35-1.25 (m, 2H), 1.34 (t, J=6.9, 3H).

CLEAVED DIENES- from PEG

penta-2E,4E-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

0.203 g (0.0385 mmol) of resin **17** was treated 2 eq of DBU in MeOH/CH₂Cl₂ according to the standard conditions, giving 0.0072g (63%) of product after column purification (2:1 EtOAc:hex).

TLC (2:1 EtOAc:hex): R_f=0.19; ¹H NMR (CDCl₃): δ 7.19 (dd, J=14.9, 11.1, 1H), 6.51 (br s, 1H), 6.42 (dt, J=16.8, 10.5, 1H), 6.40 (d, J=6.5, 1H), 5.92 (d, J=15.3, 1H), 5.57 (d, J=17.2, 1H), 5.45 (d, J=10.3, 1H), 4.56 (quint, J=7.1, 1H), 3.66 (s, 3H), 3.24 (m, 2H), 2.30 (t, J=7.4, 2H), 1.62 (br quint, J=7.5, 2H), 1.52 (br quint, J=7.4, 2H), 1.40 (d, J=6.9, 3H), 1.33 (br quint, J=7.7, 2H); MS (ES⁺): 297 (MH⁺, 100), 146 (MH⁺-151, 4).

3-(2'-furan)-prop-2Eene-1-amide-Ala-Aca-OCH₃ (18, R¹ = R³ = H, R² = R⁴ = -OCH=CH-, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

0.199 g (0.0373 mmol) of resin **17** was treated 2 eq of DBU in MeOH/CH₂Cl₂ according to the standard conditions, giving 0.0100g (79%) of product after column purification (2:1 EtOAc:hex).

TLC (2:1 EtOAc:hex): R_f=0.27; ¹H NMR (CDCl₃): δ 7.42 (d, J=1.9, 1H), 7.39 (d, J=15.3, 1H), 6.55 (d, J=3.4, 1H), 6.52 (t, J=5.5, 1H), 6.46 (d, J=7.6, 1H), 6.44 (dd, J=3.4, 1.9, 1H), 6.34 (d,

J=15.3, 1H), 4.60 (quint, J=7.2, 1H), 3.65 (s, 3H), 3.25 (q, J=6.6, 2H), 2.30 (t, J=7.4, 2H), 1.62 (br quint, J=7.5, 2H), 1.52 (br quint, J=7.3, 2H), 1.43 (d, J=7.2, 3H), 1.34 (br quint, J=7.7, 2H); MS (ES⁺): 359 (MNa⁺, 12), 337 (MH⁺, 100), 146 (MH⁺-191, 22).

3-(2'-thiophene)-prop-2Eene-1-amide-Arg(Pbf)-OCH₃ (18, R¹ = R³ = H, R² = R⁴ = -SCH=CH-, Xaa₂-Xaa₁ = Arg(Pbf)-Aca, R = Me):

O.190 g (0.0335 mmol) of resin **17** was treated 2 eq of DBU in MeOH/CH₂Cl₂ according to the standard conditions, giving 0.0177g (77%) of product after column purification (20:1 EtOAc:MeOH). TLC (9:1 EtOAc:MeOH): R_f=0.63; ¹H NMR (CDCl₃): δ 7.67 (d, J=15.3, 1H), 7.30 (br s, 1H), 7.29 (d, J=5.0, 1H), 7.15 (d, J=3.0, 1H), 7.00 (dd, J=5.0, 3.8, 1H), 6.41 (d, J=15.3, 1H), 6.33 (br s, 3H), 6.25 (vbr s, 1H), 4.62 (br s, 1H), 3.63 (s, 3H), 3.4-3.2 (m, 2H), 3.22 (m, 2H), 2.93 (s, 2H), 2.58 (s, 3H), 2.51 (s, 3H), 2.27 (t, J=7.4, 2H), 2.08 (s, 3H), 1.89 (br m, 1H), 1.77 (m, 1H), 1.65-1.45 (m, 2H), 1.59 (br quint, J=7.6, 2H), 1.52 (br quint, J=7.3, 2H), 1.44 (s, 6H), 1.31 (br quint, J=7.7, 2H); MS (ES⁺): 690 (MH⁺, 100), 337 (MH⁺-353, 22), 273 (MH⁺-417, 12), 229 (MH⁺-461, 15), 146 (MH⁺-544, 12). Anal. Calcd for CHNOS: C, 57.45; H, 6.87; N, 10.15; S, 9.29. Found: C, 57.52; H, 6.87; N, 9.90; S, 8.80.

(N,N'-dimethyl)-6-amino-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OCH₃ (18, R¹ = R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Arg(Pbf)-Aca, R = Me):

O.172 g (0.0303 mmol) of resin **17** was treated 2 eq of DBU in MeOH/CH₂Cl₂ according to the standard conditions, giving 0.0167g (80%) of product after column purification (5:1:0.1 EtOAc:MeOH:Et₃N).

TLC (12:7:1 EtOAc:MeOH:Et₃N): R_f=0.54; ¹H NMR (CDCl₃): δ 7.77 (br s, 1H), 7.41 (br s, 1H), 7.14 (dd, J=15.3, 11.1, 1H), 6.80 (br s, 1H), 6.53 (br s, 2H), 6.51 (dd, J=15.6, 11.1, 1H), 6.23 (d, J=14.9, 1H), 6.14 (dt, J=15.3, 7.3, 1H), 4.44 (br s, 1H), 3.64 (s, 6H), 3.63 (s, 3H), 3.61 (br m, 2H), 3.3-3.1 (m, 4H), 2.94 (s, 2H), 2.57 (s, 3H), 2.50 (s, 3H), 2.26 (t, J=7.4, 2H), 2.08 (s, 3H), 1.87 (br m, 1H), 1.76 (br m, 1H), 1.6-1.45 (m, 2H), 1.58 (br quint, J=7.6, 2H), 1.48 (br quint, J=7.5, 2H), 1.45 (s, 6H), 1.29 (br quint, J=7.7, 2H); MS (ES⁺): 691 (MH⁺, 15), 346 (MH⁺-345, 100).

5-carboxy-penta-2E,4E-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = R² = R³ = H, R⁴ = CO₂H, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

O.205 g (0.0370 mmol) of resin **17** was treated 2 eq of DBU in MeOH/CH₂Cl₂ according to the standard conditions, giving 0.0111g (88%) of product after column purification (10:1:0.1 EtOAc:MeOH:AcOH).

¹H NMR (CD₃CN): δ 9.4 (vbr s, 1H), 7.36 (dd, J=15.1, 11.6, 1H), 7.25 (dd, J=14.9, 11.4, 1H), 7.01 (d, J=6.9, 1H), 6.67 (br s, 1H), 6.40 (d, J=14.9, 1H), 6.21 (d, J=15.3, 1H), 4.35 (quint, J=7.1, 1H), 3.62 (s, 3H), 3.14 (q, J=6.5, 2H), 2.28 (t, J=7.4, 2H), 1.58 (br quint, J=7.5, 2H), 1.45 (br quint, J=7.3, 2H), 1.32 (d, J=7.2, 3H), 1.35-1.25 (m, 2H); MS (ES⁺): 363 (MNa⁺, 69), 341 (MH⁺, 100), 235 (MH⁺-106, 44), 153 (MH⁺-188, 15), 146 (MH⁺-195, 73), 102 (MH⁺-239, 78).

5-carboxymethyl-penta-2E,4E-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = R² = R³ = H, R⁴ = CO₂CH₃, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

O.087 g (0.0164 mmol) of resin **17** was treated 2 eq of DBU in MeOH/CH₂Cl₂ according to the standard conditions, giving 0.0039g (70%) of product after column purification (10:1 EtOAc:MeOH).

¹H NMR (CD₃CN): δ 7.35-7.25 (m, 2H), 6.53 (d, J=7.6, 1H), 6.24 (t, 1H), 6.21 (d, J=14.5, 1H), 6.18 (d, J=14.5, 1H), 4.53 (quint, J=7.1, 1H), 3.78 (s, 3H), 3.66 (s, 3H), 3.26 (q, J=6.6, 2H), 2.31 (t, J=7.4, 2H), 1.63 (br quint, J=7.5, 2H), 1.52 (br quint, J=7.3, 2H), 1.41 (d, J=6.9, 3H), 1.35-1.25 (m, 2H); MS (ES⁺): 363 (MNa⁺, 69), 341 (MH⁺, 100), 235 (MH⁺-106, 44), 153 (MH⁺-188, 15), 146 (MH⁺-195, 73), 102 (MH⁺-239, 78).

6-methoxy-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OCH₃ (18, R¹ = R² = R³ = H, R⁴ = CH₂OCH₃, Xaa₂-Xaa₁ = Arg(Pbf)-Aca, R = Me):

0.072 g (0.0127 mmol) of resin **17** was treated 2 eq of DBU in MeOH/CH₂Cl₂ according to the standard conditions, giving 0.0069g (79%) of product after column purification (20:1 EtOAc:MeOH).

¹H NMR (CDCl₃): δ 7.25 (vbr s, 1H), 7.17 (dd, J=15.3,11.1, 1H), 7.05 (br s, 1H), 6.31 (dd, J=15.3,11.1, 1H), 6.28 (br s, 2H), 6.15 (vbr s, 1H), 6.08 (dt, J=15.3,5.3, 1H), 6.00 (d, J=14.9, 1H), 4.55 (br s, 1H), 4.02 (d, J=5.3, 2H), 3.64 (s, 3H), 3.36 (s, 3H), 3.3-3.15 (m, 4H), 2.95 (s, 2H), 2.58 (s, 3H), 2.51 (s, 3H), 2.28 (t, J=7.4, 2H), 2.09 (s, 3H), 1.86 (br m, 1H), 1.75-1.45 (m, 3H), 1.60 (br quint, J=7.6, 2H), 1.52 (br quint, J=7.3, 2H), 1.46 (s, 6H), 1.31 (br quint, J=7.7, 2H); MS (ES⁺): 678 (MH⁺, 100),

CLEAVED DIENES- from WANG resin (Xaa₂-Xaa₁=Phe)**penta-2E,4E-diene-1-amide-Phe-OH (18, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Phe, R = H):**

0.0223 mmol of resin **17** was treated with TFA according to the standard conditions, giving 0.0051g (93%) of product.

¹H NMR (CD₃OD-partially soluble): δ 7.30-7.15 (m, 5H), 7.09 (dd, J=15.1, 10.9, 1H), 6.48 (dt, J=17.2, 10.3, 1H), 6.06 (d, J=15.3, 1H), 5.56 (d, J=17.2, 1H), 5.43 (d, J=10.3, 1H), 4.74 (dd, J=9.0,5.2, 1H), 3.23 (dd, J=13.9, 5.2, 1H), 2.99 (dd, J=13.9,9.0, 1H).

¹H NMR (DMSO-d₆): δ 8.41 (d, J=8.0, 1H), 7.30-7.15 (m, 5H), 6.97 (dd, J=15.1, 10.9, 1H), 6.47 (dt, J=16.8, 10.7, 1H), 6.09 (d, J=15.3, 1H), 5.58 (d, J=17.0, 1H), 5.41 (d, J=11.1, 1H), 4.50 (m, 1H), 3.08 (dd, J=13.7, 4.6, 1H), 2.88 (dd, J=13.7,9.9, 1H).

penta-2E,4E-diene-1-amide-Phe-OCH₃ (18, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Phe, R = Me):

0.021 mmol of resin **17** was treated with DBU according to the standard conditions, with the product filtered through a silica gel pad and eluted with EtOAc, giving 0.0041g (80%) of product.

¹H NMR (CDCl₃): δ 7.32-7.24 (m, 3H), 7.21 (dd, J=15.1, 11.1, 1H), 7.08 (d, J=6.5, 2H), 6.42 (dt, J=17.2, 10.5, 1H), 5.96 (d, J=7.6, 1H), 5.73 (d, J=15.3, 1H), 5.58 (d, J=16.8, 1H), 5.45 (d, J=9.9, 1H), 4.99 (dt, J=7.6,5.6, 1H), 3.74 (s, 3H), 3.20 (dd, J=13.9, 5.9, 1H), 3.15 (dd, J=13.7,5.3, 1H).

2-methylpenta-2E,4E-diene-1-amide-Phe-OH (18, R¹ = Me, R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Phe, R = H):

0.0229 mmol of resin **17** was treated with TFA according to the standard conditions, giving 0.0037g (63%) of material, with a 65:35 product:sm ratio.

¹H NMR (CD₃OD-partially soluble): δ 7.30-7.20 (m, 5H), 6.72-6.64 (m, 2H), 5.47 (d, J=14.5, 1H), 5.38 (d, J=9.2, 1H), 4.71 (dd, J=9.4, 4.8, 1H), 3.28 (dd, J=14.1, 5.0, 1H), 3.06 (dd, J=14.1,9.5, 1H), 1.88 (s, 3H).

¹H NMR (DMSO-d₆): δ 8.37 (d, J=8.4, 1H), 7.30-7.10 (m, 5H), 6.72-6.62 (m, 2H), 5.47 (d, J=16.0, 1H), 5.37 (d, J=10.3, 1H), 4.44 (m, 1H), 3.11 (dd, J=13.9, 4.4, 1H), 2.93 (dd, J=13.7,10.7, 1H), 1.82 (s, 3H); MS (ES⁺): 260 (MH⁺, 100); (ES⁻): 258 (M-H)⁻, 100.

6-hydroxyhexa-2E,4E-diene-1-amide-Phe-OH (18, R¹ = R² = R³ = H, R⁴ = CH₂OH, Xaa₂-Xaa₁ = Phe, R = H):

0.0136 mmol of resin **17** was treated with TFA according to the standard conditions, giving 0.0091g (>100%) of product.

¹H NMR (acetone-d₆): δ 7.50 (d, J=8.0, 1H), 7.26 (m, 4H), 7.20 (m, 1H), 7.17 (dd, J=15.0,10.7, 1H), 6.55 (dd, J=15.3, 10.7, 1H), 6.18 (d, J=15.0, 1H), 6.14 (dt, J=15.3,6.5, 1H), 5.03 (d, J=6.5, 2H), 4.83 (td, J=8.2,5.2, 1H), 3.24 (dd, J=13.9, 5.2 1H), 3.05 (dd, J=13.9,8.2, 1H).

2-methyl-6-hydroxyhexa-2E,4E-diene-1-amide-Phe-OH (18, R¹ = Me, R² = R³ = H, R⁴ = CH₂OH, Xaa₂-Xaa₁ = Phe, R = H):

0.0145 mmol of resin **17** was treated with TFA according to the standard conditions, giving 0.0054g (>100%) of product.

¹H NMR (acetone-d₆): δ 7.40-7.20 (m, 6H), 6.86-6.78 (m, 2H), 6.10 (dt, J=14.5, 7.0, 1H), 5.04 (d, J=6.9, 2H), 4.77 (td, J=8.5, 4.8, 1H), 3.27 (dd, J=14.1, 5.0, 1H), 3.09 (dd, J=13.7, 8.8, 1H), 1.92 (s, 3H).

6-aminohexa-2E,4E-diene-1-amide-Phe-OH (18, R¹ = R² = R³ = H, R⁴ = CH₂NH₂, Xaa₂-Xaa₁ = Phe, R = H):

0.0134 mmol of resin **17** was treated with TFA according to the standard conditions, giving 0.0091g (>100%) of product.

¹H NMR (acetone-d₆): δ 7.26 (m, 4H), 7.25-7.15 (m, 1H), 7.11 (dd, J=14.9, 11.1, 1H), 6.54 (dd, J=15.3, 11.1 1H), 6.21 (d, J=14.9 1H), 6.18 (dt, J=15.3, 6.3, 1H), 4.80 (dd, J=8.4, 5.0, 1H), 4.60 (d, J=6.1, 2H), 3.23 (dd, J=14.1, 5.0 1H), 3.03 (dd, J=14.1, 8.4, 1H); MS (ES⁺): 275 (MH⁺, 100), 258 (MH⁺-17, 35); (ES⁻): 387 ((MTFA-H)⁻, 1), 258 ((M-H)⁻, 1), 227 ((M-H)⁻-46, 100).

2-methyl-6-aminohexa-2E,4E-diene-1-amide-Phe-OH (18, R¹ = Me, R² = R³ = H, R⁴ = CH₂NH₂, Xaa₂-Xaa₁ = Phe, R = H):

0.0135mmol of resin **17** was treated with TFA according to the standard conditions, giving 0.01231g (>100%) of product.

¹H NMR (acetone-d₆): δ 7.29 (m, 4H), 7.25-7.20 (m, 1H), 6.85-6.75 (m, 2H), 6.07 (dt, J=14.5, 5.9, 1H), 4.76 (dd, J=8.8, 5.0, 1H), 4.60 (d, J=6.5, 2H), 3.26 (dd, J=13.9, 5.2, 1H), 3.08 (dd, J=13.9, 9.0, 1H), 1.89 (s, 3H); MS (ES⁺): 289 (MH⁺, 43), 272 (MH⁺-17, 100).

N,Ndimethyl-6-aminohexa-2E,4E-diene-1-amide-Phe-OH (18, R¹ = R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Phe, R = H):

0.0208mmol of resin **17** was treated with TFA according to the standard conditions, giving 0.0123g (>100%) of product.

¹H NMR (acetone-d₆): δ 7.58 (d, J=8.0, 1H), 7.26 (m, 4H), 7.25-7.20 (m, 1H), 7.16 (dd, J=15.3, 11.1, 1H), 6.69 (dd, J=14.9, 11.1 1H), 6.30 (d, J=15.3 1H), 6.26 (dt, J=15.3, 7.5, 1H), 4.84 (td, J=8.2, 5.2, 1H), 4.07 (d, J=6.9, 2H), 3.24 (dd, J=13.9, 5.2 1H), 3.07 (s, 6H), 3.04 (dd, J=14.1, 8.4, 1H).

N,N,2-trimethyl-6-aminohexa-2E,4E-diene-1-amide-Phe-OH (18, R¹ = Me, R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Phe, R = H):

0.0184 mmol of resin **17** was treated with TFA according to the standard conditions, giving 0.0068g (>100%) of impure product.

¹H NMR (acetone-d₆): δ 7.46 (d, J=7.2, 1H), 7.30 (m, 4H), 7.25-7.20 (m, 1H), 6.91 (m, 1H), 6.84 (m, 1H), 6.10 (dt, J=14.5, 7.2, 1H), 4.76 (m, 1H), 4.30 (t, J=7.4, 1H), 3.95 (br d, J=6.1, 1H), 3.29 (s, 3H), 3.27 (dd, J=14.1, 5.0, 1H), 3.06 (dd, J=13.9, 9.3, 1H), 1.91 (s, 3H).

CLEAVED DIENES- from WANG resin (Xaa₂-Xaa₁ = Ala-Aca)**penta-2E,4E-diene-1-amide-Ala-Aca-OH (18, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Ala-Aca, R=H):**

¹H NMR (acetone-d₆/CD₃OD): δ 7.13 (dd, J=15.1, 10.9, 1H), 6.48 (dt, J=17.2, 10.6, 1H), 6.13 (d, J=15.3, 1H), 5.56 (d, J=16.0, 1H), 5.40 (d, J=9.9, 1H), 4.47 (quint, J=7.4, 1H), 3.2-3.1 (m, 2H), 2.3-2.2 (m, 2H), 1.7-1.2 (m, 6H), 1.37 (d, J=7.2, 3H).

penta-2*E*,4*E*-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Ala-Aca, R=Me):

identical to product obtained from PEG resin

5-phenylpenta-2*E*,4*E*-diene-1-amide-Ala-Aca-OH (18, R¹ = R² = R³ = H, R⁴ = Ph, Xaa₂-Xaa₁ = Ala-Aca, R = H):

2*E*,4*E*:2*E*,4*Z* 87:13

¹H NMR (acetone-d₆): δ 7.55 (d, J=7.3, 2H), 7.52 (br m, 1H), 7.37 (t, J=7.4, 2H), 7.35 (dd, J=15.2, 10.5, 1H), 7.30 (d, J=7.3, 1H), 7.04 (dd, J=15.6, 10.5, 1H), 6.97 (d, J=15.8, 1H), 6.28 (d, J=15.0, 1H), 4.47 (quint, J=7.3, 1H), 3.19 (m, 2H), 2.28 (t, J=7.3, 2H), 1.7-1.2 (m, 6H), 1.31 (d, J=6.8, 3H); MS (ES⁺): 472 (MH⁺+113, 17), 359 (MH⁺, 41), 246 (MH⁺-113, 100); (ES⁻): 357 ((M-H)⁻, 30), 244 ((M-H)⁻- 113, 100).

5-phenylpenta-2*E*,4*E*-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = R² = R³ = H, R⁴ = Ph, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

2*E*,4*E*:2*E*,4*Z* 100:0

¹H NMR (CDCl₃): δ 7.5-7.3 (m, 6H), 6.9-6.8 (m, 2H), 6.21 (br s, 1H), 6.14 (d, J=7.3, 1H), 5.98 (d, J=14.9, 1H), 4.54 (quint, J=7.1, 1H), 3.66 (s, 3H), 3.26 (q, J=6.6, 2H), 2.31 (t, J=7.4, 2H), 1.7-1.2 (m, 6H), 1.42 (d, J=7.2, 3H); MS (ES⁺): 395 (MNa⁺, 11), 373 (MH⁺, 51), 282 (MNa⁺-113, 39), 260 (MH⁺-113, 100).

5-phenylpenta-2*E*,4*Z*-diene-1-amide-Ala-Aca-OH (18, R¹ = R² = R⁴ = H, R³ = Ph, Xaa₂-Xaa₁ = Ala-Aca, R = H):

2*E*,4*E*:2*E*,4*Z* 25:75

¹H NMR (acetone-d₆): δ 7.70 (dd, J=15.0,12.0, 1H), 7.55 (br m, 1H), 7.42 (t, J=7.3, 2H), 7.37 (d, J=6.0, 2H), 7.43 (d, J=7.3, 1H), 6.79 (d, J=11.5, 1H), 6.42 (t, J=11.8, 1H), 6.32 (d, J=15.0, 1H), 4.46 (quint, J=7.3, 1H), 3.18 (m, 2H), 2.27 (m, 2H), 1.7-1.2 (m, 6H), 1.30 (d, J=7.3, 3H); MS (ES⁺): 472 (MH⁺+113, 13), 359 (MH⁺, 32), 246 (MH⁺-113, 100); (ES⁻): 357 ((M-H)⁻, 21), 244 ((M-H)⁻- 113, 100).

5-phenylpenta-2*E*,4*Z*-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = R² = R⁴ = H, R³ = Ph, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

2*E*,4*E*:2*E*,4*Z* 22:78

¹H NMR (CDCl₃): δ 7.76 (dd, J=14.9,11.8, 1H), 7.4-7.25 (m, 6H), 6.78 (d, J=11.4, 1H), 6.34 (t, J=11.4, 1H), 6.18 (br s, 1H), 6.14 (d, J=7.3, 1H), 6.02 (d, J=14.9, 1H), 4.52 (quint, J=7.2, 1H), 3.66 (s, 3H), 3.25 (q, J=6.7, 2H), 2.30 (t, J=7.4, 2H), 1.7-1.2 (m, 6H), 1.40 (d, J=6.9, 3H); MS (ES⁺): 373 (MH⁺, 29), 282 (MNa⁺-113, 12), 260 (MH⁺-113, 100).

2-methyl-5-phenylpenta-2*E*,4*E*-diene-1-amide-Ala-Aca-OH (18, R¹ = Me, R² = R³ = H, R⁴ = Ph, Xaa₂-Xaa₁ = Ala-Aca, R = H):

2*E*,4*E*:2*E*,4*Z* 89:11

¹H NMR (acetone-d₆): δ 7.58 (d, J=7.3, 2H), 7.4-7.25 (br m, 2H), 7.36 (t, J=7.5, 2H), 7.29 (d, J=7.3, 1H), 7.26 (dd, J=15.4,11.1, 1H), 7.11 (d, J=11.1, 1H), 6.87 (d, J=15.4, 1H), 4.54 (quint, J=7.3, 1H), 3.21 (m, 2H), 2.28 (m, 2H), 2.09 (s, 3H), 1.7-1.2 (m, 6H), 1.34 (d, J=6.8, 3H); MS (ES⁺): 508 (MNa⁺+113, 5), 486 (MH⁺+113, 24), 395, (MNa⁺, 15), 373 (MH⁺,72), 260 (MH⁺-113, 100).

2-methyl-5-phenylpenta-2*E*,4*E*-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = Me, R² = R³ = H, R⁴ = Ph, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

2*E*,4*E*:2*E*,4*Z* 90:10

^1H NMR (CDCl_3): δ 7.47 (d, $J=7.2$, 2H), 7.35 (t, $J=7.4$, 2H), 7.29 (d, $J=8.4$, 1H), 7.12 (dm, $J=11.1$, 1H), 7.04 (dd, $J=15.1$, 11.3, 1H), 6.84 (d, $J=15.3$, 1H), 6.42 (d, $J=6.9$, 1H), 6.22 (br s, 1H), 4.53 (quint, $J=7.2$, 1H), 3.66 (s, 3H), 3.27 (q, $J=6.6$, 2H), 2.31 (t, $J=7.4$, 2H), 2.07 (d, $J=1.1$, 3H), 1.7-1.2 (m, 6H), 1.43 (d, $J=7.2$, 3H); MS (ES^+): 409 (MNa^+ , 4), 387 (MH^+ , 35), 274 (MH^+-113 , 98), 171 (MH^+-216 , 100).

2-methyl-5-phenylpenta-2E,4Zdiene-1-amide-Ala-Aca-OH (18, $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{R}^4 = \text{H}$, $\text{R}^3 = \text{Ph}$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{H}$):

2E,4E:2E,4Z 16:84

^1H NMR (acetone- d_6): δ 7.45 (d, $J=12.0$, 1H), 7.45-7.2 (m, 7H), 6.76 (d, $J=11.5$, 1H), 6.59 (t, $J=11.8$, 1H), 4.52 (quint, $J=7.3$, 1H), 3.19 (m, 2H), 2.35-2.25 (m, 2H), 2.06 (s, 3H), 1.7-1.2 (m, 6H), 1.41 (d, $J=7.3$, 3H); MS (ES^+): 486 (MH^++113 , 22), 395, (MNa^+ , 12), 373 (MH^+ , 59), 260 (MH^+-113 , 100).

2-methyl-5-phenylpenta-2E,4Zdiene-1-amide-Ala-Aca-OCH₃ (18, $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{R}^4 = \text{H}$, $\text{R}^3 = \text{Ph}$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{Me}$):

2E,4E:2E,4Z 22:78

^1H NMR (CDCl_3): δ 7.5-7.25 (m, 5H), 7.36 (d, $J=11.1$, 1H), 6.76 (d, $J=11.8$, 1H), 6.49 (t, $J=11.6$, 1H), 6.32 (d, $J=7.6$, 1H), 6.21 (br s, 1H), 4.50 (quint, $J=7.2$, 1H), 3.66 (s, 3H), 3.25 (q, $J=6.6$, 2H), 2.30 (t, $J=7.4$, 2H), 2.06 (d, $J=1.1$, 3H), 1.7-1.2 (m, 6H), 1.39 (d, $J=6.9$, 3H); MS (ES^+): 409 (MNa^+ , 6), 387 (MH^+ , 57), 274 (MH^+-113 , 100), 171 (MH^+-216 , 100).

trideca-2E,4E-diene-1-amide-Ala-Aca-OH (18, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = (\text{CH}_2)_7\text{CH}_3$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{H}$):

2E,4E:2E,4Z 88:12

^1H NMR (acetone- d_6): δ 11.1 (vbr s, 1H), 7.42 (d, $J=6.9$, 1H), 7.14 (dd, $J=14.9, 10.7$, 1H), 6.21 (dd, $J=15.3, 10.7$, 1H), 6.10 (dt, $J=15.3, 7.3$, 1H), 6.04 (d, $J=15.3$, 1H), 4.44 (quint, $J=7.1$, 1H), 3.18 (m, 2H), 2.27 (t, $J=7.6$, 2H), 2.16 (q, $J=7.1$, 2H), 1.7-1.2 (m, 18H), 1.39 (d, $J=7.2$, 3H), 0.88 (t, $J=6.9$, 3H); MS (ES^+): 395 (MH^+ , 14), 282 (MH^+-113 , 100); (ES^-): 393 ($(\text{M-H})^-$, 33), 280 ($(\text{M-H})^-$, 113, 100).

trideca-2E,4E-diene-1-amide-Ala-Aca-OCH₃ (18, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = (\text{CH}_2)_7\text{CH}_3$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{Me}$):

2E,4E:2E,4Z 90:10

^1H NMR (CDCl_3): δ 7.20 (dd, $J=15.1, 10.1$, 1H), 6.21 (br s, 1H), 6.15-6.05 (m, 2H), 6.01 (d, $J=7.6$, 1H), 5.75 (d, $J=14.9$, 1H), 4.51 (quint, $J=7.2$, 1H), 3.66 (s, 3H), 3.25 (q, $J=6.7$, 2H), 2.31 (t, $J=7.4$, 2H), 2.15 (q, $J=6.9$, 2H), 1.7-1.2 (m, 18H), 1.39 (d, $J=6.9$, 3H), 0.88 (t, $J=7.1$, 3H); MS (ES^+): 431 (MNa^+ , 5), 409 (MH^+ , 93), 296 (MH^+-113 , 100).

trideca-2E,4Zdiene-1-amide-Ala-Aca-OH (18, $\text{R}^1 = \text{R}^2 = \text{R}^4 = \text{H}$, $\text{R}^3 = (\text{CH}_2)_7\text{CH}_3$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{H}$):

2E,4E:2E,4Z 24:76

^1H NMR (acetone- d_6): δ 7.50 (dd, $J=15.0, 10.7$, 1H), 7.48 (d, $J=6.0$, 1H), 6.14 (t, $J=11.5$, 1H), 6.12 (d, $J=15.0$, 1H), 5.79 (dt, $J=10.7, 7.7$, 1H), 4.45 (quint, $J=7.3$, 1H), 3.18 (m, 2H), 2.30 (q, $J=7.5$, 2H), 2.28 (m, 2H), 1.7-1.2 (m, 18H), 1.40 (d, $J=7.3$, 3H), 0.87 (t, $J=7.1$, 3H); MS (ES^+): 395 (MH^+ , 17), 282 (MH^+-113 , 100); (ES^-): 393 ($(\text{M-H})^-$, 13), 280 ($(\text{M-H})^-$, 113, 100).

trideca-2E,4Zdiene-1-amide-Ala-Aca-OCH₃ (18, $\text{R}^1 = \text{R}^2 = \text{R}^4 = \text{H}$, $\text{R}^3 = (\text{CH}_2)_7\text{CH}_3$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{Me}$):

2E,4E:2E,4Z 23:77

^1H NMR (CDCl_3): δ 7.57 (dd, $J=14.9, 11.8$, 1H), 6.20 (br s, 1H), 6.15-6.00 (m, 2H), 6.09 (t, $J=11.3$, 1H), 5.86 (d, $J=14.9$, 1H), 4.53 (quint, $J=7.2$, 1H), 3.66 (s, 3H), 3.25 (q, $J=6.7$, 2H), 2.35-2.25 (m, 4H), 1.7-1.2 (m, 18H), 1.40 (d, $J=6.9$, 3H), 0.88 (t, $J=6.7$, 3H); MS (ES^+): 409 (MH^+ , 22), 330 (MH^+-79 , 100), 296 (MH^+-113 , 83).

2-methyltrideca-2*E*,4*E*-diene-1-amide-Ala-Aca-OH (18, $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = (\text{CH}_2)_7\text{CH}_3$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{H}$):
2*E*,4*E*:2*E*,4*Z* 94:6

^1H NMR (acetone- d_6): δ 7.3-7.2 (br m, 2H), 6.90 (d, $J=11.1$, 1H), 6.41 (dd, $J=15.0, 11.1$, 1H), 6.01 (dt, $J=15.0, 7.3$), 4.50 (quint, $J=7.3$, 1H), 3.17 (m, 2H), 2.30 (t, $J=7.4$, 2H), 2.19 (q, $J=7.4$, 2H), 1.93 (s, 3H), 1.7-1.2 (m, 18H), 1.42 (d, $J=7.3$, 3H), 0.88 (m, 3H); MS (ES^+): 522 (MH^++113 , 5), 409 (MH^+ , 13), 296 (MH^+-113 , 100).

2-methyltrideca-2*E*,4*E*-diene-1-amide-Ala-Aca-OCH₃ (18, $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = (\text{CH}_2)_7\text{CH}_3$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{Me}$):
2*E*,4*E*:2*E*,4*Z* 85:15

^1H NMR (CDCl_3): δ 6.90 (d, $J=10.9$, 1H), 6.35-6.20 (br m, 2H), 6.30 (dd, $J=15.1, 10.9$, 1H), 6.03 (dt, $J=14.9, 7.2$), 4.50 (quint, $J=7.2$, 1H), 3.66 (s, 3H), 3.25 (q, $J=6.7$, 2H), 2.31 (t, $J=7.4$, 2H), 2.17 (q, $J=7.1$, 2H), 1.94 (s, 3H), 1.7-1.2 (m, 18H), 1.40 (d, $J=6.9$, 3H), 0.88 (t, $J=6.9$, 3H); MS (ES^+): 445 (MNa^+ , 3), 423 (MH^+ , 37), 310 (MH^+-113 , 100).

2-methyltrideca-2*E*,4*Z*-diene-1-amide-Ala-Aca-OH (18, $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{R}^4 = \text{H}$, $\text{R}^3 = (\text{CH}_2)_7\text{CH}_3$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{H}$):
2*E*,4*E*:2*E*,4*Z* 18:82

^1H NMR (acetone- d_6): δ 7.4-7.2 (br m, 2H), 7.27 (d, $J=11.5$, 1H), 6.32 (t, $J=11.3$, 1H), 5.76 (dt, $J=10.7, 7.9$, 1H), 4.51 (quint, $J=7.3$, 1H), 3.19 (m, 2H), 2.35-2.25 (m, 4H), 1.95 (s, 3H), 1.7-1.2 (m, 18H), 1.42 (d, $J=7.3$, 3H), 0.87 (m, 3H); MS (ES^+): 522 (MH^++113 , 21), 431 (MNa^+ , 8), 409 (MH^+ , 61), 296 (MH^+-113 , 100).

2-methyltrideca-2*E*,4*Z*-diene-1-amide-Ala-Aca-OCH₃ (18, $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{R}^4 = \text{H}$, $\text{R}^3 = (\text{CH}_2)_7\text{CH}_3$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{Me}$):
2*E*,4*E*:2*E*,4*Z* 15:85

^1H NMR (CDCl_3): δ 7.29 (d, $J=10.7$, 1H), 6.37 (d, $J=7.2$, 1H), 6.24 (t, $J=11.3$, 1H), 5.80 (dt, $J=11.4, 7.4$, 1H), 4.52 (quint, $J=7.2$, 1H), 3.66 (s, 3H), 3.26 (m, 2H), 2.30 (q, $J=7.2$, 2H), 2.28 (t, $J=7.5$, 2H), 1.95 (s, 3H), 1.7-1.2 (m, 18H), 1.42 (d, $J=6.9$, 3H), 0.88 (t, $J=6.7$, 3H); MS (ES^+): 445 (MNa^+ , 12), 423 (MH^+ , 75), 310 (MH^+-113 , 100).

3-(2'-furan)-prop-2*E*-ene-1-amide-Ala-Aca-OH (18, $\text{R}^1 = \text{R}^3 = \text{H}$, $\text{R}^2 = \text{R}^4 = -\text{OCH}=\text{CH}-$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{H}$):

^1H NMR (acetone- d_6): δ 7.63 (s, 1H), 7.33 (d, $J=15.8$, 1H), 6.71 (t, $J=3.2$, 1H), 6.56 (d, $J=15.4$, 1H), 6.54 (d, $J=3.4$, 1H), 4.48 (quint, $J=7.3$, 1H), 3.19 (m, 2H), 2.27 (m, 2H), 1.7-1.2 (m, 6H), 1.32 (d, $J=7.3$, 3H); MS (ES^+): 436 (MH^++113 , 8), 323 (MH^+ , 27), 208 (MH^+-113 , 15), 187 (MH^+-136 , 100); (ES^-): 332 ((M-H) $^-$, 74), 208 ((M-H) $^-$, 113, 100).

3-(2'-furan)-prop-2*E*-ene-1-amide-Ala-Aca-OCH₃ (18, $\text{R}^1 = \text{R}^3 = \text{H}$, $\text{R}^2 = \text{R}^4 = -\text{OCH}=\text{CH}-$, $\text{Xaa}_2\text{-Xaa}_1 = \text{Ala-Aca}$, $\text{R} = \text{Me}$):

^1H NMR (CDCl_3): δ 7.44 (d, $J=1.1$, 1H), 7.40 (d, $J=15.3$, 1H), 6.56 (d, $J=3.4$, 1H), 6.45 (dd, $J=3.4, 1.5$, 1H), 6.31 (d, $J=15.3$, 1H), 6.23 (br s, 1H), 6.19 (d, $J=7.2$, 1H), 4.56 (quint, $J=7.2$, 1H), 3.66 (s, 3H), 3.26 (m, 2H), 2.31 (t, $J=7.4$, 2H), 1.7-1.2 (m, 6H), 1.42 (d, $J=7.2$, 3H).

2-methyl-3-(2'-furan)-prop-2Eene-1-amide-Ala-Aca-OH (18, R¹ = Me, R³ = H, R² = R⁴ = -OCH=CH-, Xaa₂-Xaa₁ = Ala-Aca, R = H):

¹H NMR (acetone-d₆): δ 7.68 (d, J=1.7, 1H), 7.45 (br m, 2H), 7.18 (d, J=0.9, 1H), 6.67 (d, J=3.4, 1H), 6.57 (dd, J=3.4,1.7, 1H), 4.54 (quint, J=7.3, 1H), 3.17 (m, 2H), 2.30 (m, 2H), 2.22 (d, J=1.3, 3H), 1.7-1.2 (m, 6H), 1.45 (d, J=7.3, 3H).

2-methyl-3-(2'-furan)-prop-2Eene-1-amide-Ala-Aca-OCH₃ (18, R¹ = Me, R³ = H, R² = R⁴ = -OCH=CH-, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

¹H NMR (CDCl₃): δ 7.50 (d, J=1.1, 1H), 7.20 (d, J=0.8, 1H), 6.55 (d, J=3.4, 1H), 6.47 (dd, J=3.4,1.9, 1H), 6.5-6.4 (br m, 1H), 6.20 (br s, 1H), 4.53 (quint, J=7.2, 1H), 3.66 (s, 3H), 3.27 (q, J=6.7, 2H), 2.31 (t, J=7.4, 2H), 2.26 (d, J=0.8, 3H), 1.7-1.2 (m, 6H), 1.43 (d, J=6.9, 3H).

6-hydroxy-hexa-2E,4E-diene-1-amide-Ala-Aca-OH (18, R¹ = R² = R³ = H, R⁴ = CH₂OH, Xaa₂-Xaa₁ = Ala-Aca, R = H):

2E,4E:2E,4Z 99:1

¹H NMR (acetone-d₆): δ 7.42 (d, J=7.3, 1H), 7.28 (br s, 1H), 7.20 (dd, J=15.0,11.1, 1H), 6.59 (dd, J=15.4, 11.1, 1H), 6.27 (d, J=15.4), 6.24 (dt, J=15.4,6.3, 1H), 5.04 (d, J=6.4, 2H), 4.45 (quint, J=7.3, 1H), 3.18 (m, 2H), 2.27 (t, J=7.4, 2H), 1.7-1.2 (m, 6H), 1.30 (d, J=7.3, 3H); MS (ES⁺): 313 (MH⁺, 13), 200 (MH⁺-113, 41), 187 (MH⁺-126, 100).

6-hydroxy-hexa-2E,4E-diene-1-amide-Ala-Aca-OPEG-OCH₃ (18, R¹ = R² = R³ = H, R⁴ = CH₂OH, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

2E,4E:2E,4Z 100:0

¹H NMR (CDCl₃): δ 7.25 (dd, J=15.3,10.7, 1H), 6.39 (dd, J=15.3, 11.1, 1H), 6.29 (br s, 1H), 6.25 (d, J=8.0), 6.20 (dt, J=15.3,4.9, 1H), 5.88 (d, J=14.9, 1H), 4.53 (quint, J=7.2, 1H), 4.29 (dd, J=5.0,1.1, 2H), 3.66 (s, 3H), 3.25 (m, 2H), 2.30 (t, J=7.4, 2H), 1.7-1.2 (m, 6H), 1.40 (d, J=6.9, 3H); MS (ES⁺): 349 (MNa⁺, 20), 327 (MH⁺, 32), 214 (MH⁺-113, 100).

6-hydroxy-hexa-2E,4Zdiene-1-amide-Ala-Aca-OPEG-OH (18, R¹ = R² = R⁴ = H, R³ = CH₂OH, Xaa₂-Xaa₁ = Ala-Aca, R = H):

2E,4E:2E,4Z 8:92; EE+EZ:gem 67:33

¹H NMR (acetone-d₆): δ 7.50 (dd, J=15.0,12.0, 1H), 6.47 (t, J=11.8, 1H), 6.30 (d, J=15.0), 5.93 (dt, J=10.7,7.3, 1H), 5.23 (d, J=7.3, 2H), 4.46 (q, J=6.8, 1H), 3.19 (m, 2H), 2.27 (t, J=7.4, 2H), 1.7-1.2 (m, 6H), 1.30 (d, J=7.3, 3H); MS (ES⁺): 426 (MH⁺+113, 17), 338 (MH⁺+25, 100), 313 (MH⁺, 38), 200 (MH⁺-113, 68), 187 (MH⁺-126, 74),.

6-hydroxy-hexa-2E,4Zdiene-1-amide-Ala-Aca-OPEG-OCH₃ (18, R¹ = R² = R⁴ = H, R³ = CH₂OH, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

2E,4E:2E,4Z 10:90; EE+EZ:gem 65:35

¹H NMR (CDCl₃): δ 7.53 (dd, J=15.3,10.7, 1H), 6.18 (t, J=11.1, 1H), 6.00-5.90 (m, 2H), 4.53 (m, 1H), 4.45 (d, J=6.8, 2H), 3.66 (s, 3H), 3.25 (m, 2H), 2.30 (m, 2H), 1.7-1.2 (m, 6H), 1.40 (d, J=6.9, 3H); MS (ES⁺): 349 (MNa⁺, 40), 327 (MH⁺, 43), 214 (MH⁺-113, 77), 199 (MH⁺-128, 100).

(N,N-dimethyl)-6-amino-hexa-2E,4E-diene-1-amide-Ala-Aca-OH (18, R¹ = R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Ala-Aca, R = H):

2E,4E:2E,4Z 94:6

¹H NMR (acetone-d₆): δ 7.51 (d, J=7.3, 1H), 7.30 (br s, 1H), 7.20 (dd, J=15.2,10.9, 1H), 6.67 (dd, J=15.4,11.1, 1H), 6.27 (d, J=15.0, 1H), 6.25 (dt, J=15.0,7.5, 1H), 4.45 (quint, J=7.3, 1H), 3.92 (d, J=7.3, 2H), 3.19 (m, 2H), 2.90 (s, 6H), 2.27 (t, J=7.4, 2H), 1.7-1.2 (m, 6H), 1.30 (d, J=6.8, 3H); MS (ES⁺): 453 (MH⁺+113, 4), 340 (MH⁺, 38), 227 (MH⁺-113, 100).

(N,N-dimethyl)-6-amino-hexa-2E,4E-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

crude product, DBU present

2E,4E:2E,4Z >90:<10

¹H NMR (CDCl₃): δ 7.15 (dd, J=15.1,10.9, 1H), 6.24 (dd, J=15.1,11.3, 1H), 6.00 (dt, J=15.3,7.2, 1H), 5.88 (d, J=15.3, 1H), 4.29 (quint, J=6.8, 1H), 2.98 (d, J=6.5, 2H), 2.31 (m, 2H), 2.21 (s, 6H), 1.7-1.2 (m, 6H), 1.37 (d, J=6.9, 3H); MS (ES⁺): only see DBU 171 (MNa⁺, 60), 153 (MH⁺, 100).

(N,N'-dimethyl)-2-methyl-6-amino-hexa-2E,4E-diene-1-amide-Ala-Aca-OH (18, R¹ = Me, R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Ala-Aca, R = H):

2E,4E:2E,4Z >90:<10

¹H NMR (acetone-d₆): δ 7.35 (d, J=6.4, 1H), 7.00-6.90 (m, 2H), 6.12 (dt, J=14.5,7.3, 1H), 4.44 (quint, J=7.3, 1H), 3.96 (d, J=7.3, 2H), 3.19 (m, 2H), 2.88 (s, 6H), 2.27 (m, 2H), 1.98 (s, 3H), 1.7-1.2 (m, 6H), 1.32 (d, J=7.3, 3H); MS (ES⁺): 467 (MH⁺+113, 11), 354 (MH⁺, 37), 241 (MH⁺+113, 100).

(N,N'-dimethyl)-2-methyl-6-amino-hexa-2E,4E-diene-1-amide-Ala-Aca-OCH₃ (18, R¹ = Me, R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Ala-Aca, R = Me):

crude product, DBU present

2E,4E:2E,4Z >90:<10

¹H NMR (CDCl₃): δ 6.93 (d, J=11.1, 1H), 6.41 (dd, J=15.3,11.1, 1H), 5.95 (dt, J=14.9,7.3, 1H), 4.27 (quint, J=6.5, 1H), 3.00 (d, J=6.9, 2H), 2.23 (t, J=7.4, 2H), 2.21 (s, 6H), 1.97 (s, 3H), 1.7-1.2 (m, 6H), 1.44 (d, J=6.9, 3H); MS (ES⁺): mainly DBU 171 (MNa⁺, 65), 153 (MH⁺, 100); trace 368 (MH⁺, 1),

CLEAVED DIENES- from WANG resin (Xaa₂-Xaa₁ = Arg-Aca)

pent-2Eene-1-amide-Arg(Pbf)-OCH₃ (18, R¹ = R² = R³ = R⁴ = H, Xaa₂-Xaa₁ = Arg(Pbf)-Aca, R = Me):

¹H NMR (CDCl₃): δ 7.25-7.15 (m, 1H), 7.0 (br s, 1H), 6.60 (br s, 2H), 6.50-6.35 (m, 1H), 6.00 (d, J=14.9, 1H), 5.57 (d, J=17.2, 1H), 5.46 (d, J=10.3, 1H), 5.4 (br s, 1H), 4.51 (br m, 1H), 3.65 (s, 3H), 3.5-3.1 (m, 4H), 2.96 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.30 (t, J=7.4, 2H), 2.10 (s, 3H), 2.0-1.2 (m, 10H), 1.47 (s, 6H); MS (ES⁺): 634 (MH⁺, 50), 521 (MH⁺+113, 100).

3-(2'-thiophene)-prop-2Eene-1-amide-Arg(Pbf)-OH (18, R¹ = R³ = H, R² = R⁴ = -SCH=CH-, Xaa₂-Xaa₁ = Arg(Pbf)-Aca, R = H):

¹H NMR (CD₃OD): δ 7.69 (d, J=15.6, 1H), 7.49 (d, J=5.3, 1H), 7.31 (d, J=3.0, 1H), 7.08 (dd, J=5.0,3.8, 1H), 6.50 (d, J=15.3, 1H), 4.44 (dd, J=8.4,5.7, 1H), 3.3-3.1 (m, 4H), 2.30 (t, J=7.4, 2H), 2.2-1.3 (m, 10H); MS (ES⁺): 537 (MH⁺+113, 12), 424 (MH⁺, 50), 311 (MH⁺+113, 100).

3-(2'-thiophene)-prop-2Eene-1-amide-Arg(Pbf)-OCH₃ (18, R¹ = R³ = H, R² = R⁴ = -SCH=CH-, Xaa₂-Xaa₁ = Arg(Pbf)-Aca, R = Me):

¹H NMR identical to product obtained from PEG resin

(N,N'-dimethyl)-6-amino-hexa-2E,4E-diene-1-amide-Arg(Pbf)-Aca-OH (18, R¹ = R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Arg(Pbf)-Aca, R = H):

¹H NMR (CD₃OD): δ 7.22 (dd, J=15.6,10.2, 1H), 6.70 (dd, J=14.8,10.2, 1H), 6.35 (d, J=14.8, 1H), 6.15 (dt, J=14.8,7.0, 1H), 4.38 (m, 1H), 3.86 (d, J=7.6, 2H), 3.30-3.15 (m, 4H), 2.88 (s,

6H), 2.29 (t, J=7.2, 2H), 2.20-1.30 (m, 10H); MS (ES⁺): 538 (MH⁺+113, 4), 425 (MH⁺, 8), 312 (MH⁺-113, 28), 213 (MH⁺-212, 72), 157 (MH⁺-268, 100).

(N,N'dimethyl)-6-amino-hexa-2*E*,4*E*-diene-1-amide-Arg(Pbf)-Aca-OCH₃, (18, R¹ = R² = R³ = H, R⁴ = CH₂NMe₂, Xaa₂-Xaa₁ = Arg(Pbf)-Aca, R = Me):

¹H NMR identical to product obtained from PEG resin

1H), 1.7-1.2 (m, 9H), 1.44 (s, 6H).

DBU cleavage gave very little product, MS (ES⁺): 841 (MH⁺+30, 16), 841 (MH⁺, 4).

Table 3. Summary of Stille Reaction Conditions to Prepare 17 (see Scheme 4)

Entry	R ¹	R ²	R ³	R ⁴	Xaa ₂	Xaa ₁	P	$\frac{\alpha}{\text{Pd}_2\text{dba}_3 / \text{eq AsPh}_3}$	α R ₃ SnR ₃	T (°C)	time (h)	prod: sm ^a	isomer ratio ^b	diene cleaved yield ^c (%)
1	H	H	H	H	-	Gly	PEG	0.025/0.1	1.2	rt	o/n	95:5	100:0	-
2	H	H	H	H	Ala	Aca	PEG	0.1/0.4	1.2	rt	1	100:0	>95:<5	R=Me (63)
3	H	H	H	H	Arg(Pbf)	Aca	PEG	0.1/0.4	1.2	rt	3.5	100:0	>95:<5	-
4	H	H	H	H	-	Phe	Wang	0.1/0.4	2	rt	o/n	100:0	>95:<5	R=H (93)
5	H	H	H	H	Ala	Aca	Wang	0.1/0.4	2	rt	o/n	100:0	>95:<5	R=Me (80)
6	H	H	H	H	Arg(Pbf)	Aca	Wang	0.2/0.8	2	rt	o/n	100:0	>95:<5	R=H
7	Me	H	H	H	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	15:85	>95:<5	R=Me
8	Me	H	H	H	Ala	Aca	PEG	0.2/0.8	5	40	o/n	52:48	>95:<5	-
9	Me	H	H	H	Ala	Aca	PEG	0.2/0.8	10	60	o/n	87:13	>95:<5	-
10	Me	H	H	H	-	Phe	Wang	0.2/0.8	10	60	o/n	65:35	>95:<5	R=H (63)
11	Me	H	H	H	Ala	Aca	Wang	0.2/0.8	10	60	o/n	-	-	-
12	H	H	H	Ph	-	Gly	PEG	0.025/0.1	1.5	rt	o/n	95:5	100:0	-
13	H	H	H	Ph	Ala	Aca	PEG	0.1/0.4	1.2	rt	o/n	100:0	>85:<15	-
14	H	H	H	Ph	Arg(Pbf)	Aca	PEG	0.1/0.4	1.2	rt	o/n	100:0	>85:<15	-
15	H	H	H	Ph	Ala	Aca	Wang	0.1/0.4	2	rt	o/n	100:0	87:13	R=H
16	H	H	Ph	H	Ala	Aca	Wang	0.2/0.8	5	60	o/n	100:0	100:0	R=Me
17	Me	H	H	Ph	Ala	Aca	Wang	0.2/0.8	10	60	o/n	100:0	25:75	R=H
18	Me	H	Ph	H	Ala	Aca	Wang	0.2/0.8	10	60	o/n	100:0	22:78	R=Me
19	H	H	H	tBu	-	Gly	PEG	0.025/0.1	1.5	rt	1	2:98	-	-
20	H	H	H	tBu	-	Gly	PEG	0.025/0.1	1.5	rt	o/n	40:60	39:51:10	-
21	H	H	H	tBu	-	Gly	PEG	0.1/0.4	1.2	rt	o/n	100:0	41:48:11	-
22	H	H	H	tBu	-	Gly	PEG	0.1/0.4	1.2	rt	o/n	100:0	87:11:2	-
23	H	H	H	tBu	Ala	Aca	PEG	0.2/0.8	10	rt	o/n	100:0	79:21	-
24	H	H	H	tBu	Arg(Pbf)	Aca	PEG	0.2/0.8	10	rt	o/n	100:0	89:11	-
25	H	H	H	(CH ₂) ₇ CH ₃	Ala	Aca	PEG	0.1/0.4	2.5	rt	o/n	100:0	83:17	-
26	H	H	H	(CH ₂) ₇ CH ₃	Arg(Pbf)	Aca	PEG	0.1/0.4	2.5	rt	0/n	100:0	71:29	-
27	H	H	H	(CH ₂) ₇ CH ₃	Ala	Aca	Wang	0.1/0.4	2	rt	o/n	100:0	88:12	R=H
												100:0	90:10	R=Me

28	H	H	(CH ₂) ₇ CH ₃	H	Ala	Aca	Wang	0.2/0.8	5	60	o/n	100:0	24:76	R=H
29	Me	H	H	(CH ₂) ₇ CH ₃	Ala	Aca	Wang	0.2/0.8	10	60	o/n	100:0	23:77	R=Me
30	Me	H	(CH ₂) ₇ CH ₃	H	Ala	Aca	Wang	0.2/0.8	10	60	o/n	100:0	94:6	R=H
												100:0	85:15	R=Me
												100:0	18:82	R=H
												100:0	15:85	R=Me
31	H	=R ⁴	H	-CH=CH-O-	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>95:<5	R=Me (79)
32	H	=R ⁴	H	-CH=CH-O-	Arg(Pbf)	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>95:<5	-
33	H	=R ⁴	H	-CH=CH-O-	Ala	Aca	Wang	0.1/0.4	2	rt	o/n	100:0	>95:<5	R=H
												100:0	>95:<5	R=Me
34	Me	=R ⁴	H	-CH=CH-O-	Ala	Aca	Wang	0.2/0.8	5	60	o/n	100:0	>95:<5	R=H
												100:0	>95:<5	R=Me
35	H	=R ⁴	H	-CH=CH-S-	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>95:<5	-
36	H	=R ⁴	H	-CH=CH-S-	Arg(Pbf)	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>95:<5	R=Me (77)
37	H	=R ⁴	H	-CH=CH-S-	Arg(Pbf)	Aca	Wang	0.1/0.4	2	rt	o/n	100:0	>95:<5	R=H
												100:0	>95:<5	R=Me
38	H	H	H	CH ₂ OH	Ala	Aca	PEG	0.1/0.4	2	rt	o/n	100:0	>95:<5	-
39	H	H	H	CH ₂ OH	Arg(Pbf)	Aca	PEG	0.1/0.4	2	rt	o/n	100:0	>95:<5	-
40	H	H	H	CH ₂ OH	-	Phe	Wang	0.1/0.4	2	rt	o/n	100:0	>95:<5	-
41	H	H	H	CH ₂ OH	Ala	Aca	Wang	0.1/0.4	2	rt	o/n	100:0	99:1	R=H
												100:0	100:0	R=Me
42	H	H	CH ₂ OH	H	Ala	Aca	PEG	0.2/0.8	3	60	o/n	100:0	0:80:20	-
43	H	H	CH ₂ OH	H	Ala	Aca	Wang	0.2/0.8	5	60	o/n	100:0	8:92	R=H
												100:0	10:90	R=Me
44	Me	H	H	CH ₂ OH	-	Phe	Wang	0.2/0.8	10	60	o/n	100:0	>95:<5	R=H (>90)
48	H	H	H	CH ₂ NH ₂	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	58:42	>95:<5	-
49	H	H	H	CH ₂ NH ₂	Ala	Aca	PEG	0.2/0.8	3	rt	o/n	100:0	>95:<5	-
50	H	H	H	CH ₂ NH ₂	Arg(Pbf)	Aca	PEG	0.1/0.4	1.5	rt	o/n	50:50	>95:<5	-
51	H	H	H	CH ₂ NH ₂	Arg(Pbf)	Aca	PEG	0.2/0.8	3	rt	o/n	100:0	>90:<10	-
52	H	H	H	CH ₂ NHBoc	Ala	Aca	PEG	0.1/0.4	2.5	rt	o/n	100:0	>95:<5	-
53	H	H	H	CH ₂ NHBoc	Arg(Pbf)	Aca	PEG	0.1/0.4	2.5	rt	o/n	100:0	>95:<5	-
54	H	H	H	CH ₂ NHBoc	-	Phe	Wang	0.1/0.4	2	rt	o/n	100:0	>95:<5	R=H ^d (>90)
55	Me	H	H	CH ₂ NHBoc	Ala	Aca	PEG	0.2/0.8	5	40	o/n	90:10	>95:<5	-
56	Me	H	H	CH ₂ NHBoc	Ala	Aca	PEG	0.2/0.8	10	60	o/n	100:0	>95:<5	-
57	Me	H	H	CH ₂ NHBoc	-	Phe	Wang	0.2/0.8	10	60	o/n	100:0	>95:<5	R=H ^d (>90)
58	H	H	H	CH ₂ NMe ₂	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>95:<5	-
59	H	H	H	CH ₂ NMe ₂	Arg(Pbf)	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>95:<5	R=Me (80)

77	Me	OEi	H	H	H	-	Gly	PEG	0.1/0.4	1.2	rt	o/n	100:0	>90:<10	-
76	Me	OEi	H	H	H	Ala	Aca	PEG	0.2/0.8	10	rt	o/n	55:45	>90:<10	-
75	H	OEi	H	H	H	Arg(Pbf)	Aca	PEG	0.1/0.4	1.2	rt	o/n	100:0	>90:<10	-
74	H	OEi	H	H	H	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>90:<10	-
73	H	OEi	H	H	H	Ala	Aca	PEG	0.1/0.4	1.2	rt	3.5	74:26	90:10	-
72	H	OEi	H	H	H	-	Gly	PEG	0.1/0.4	1.2	rt	o/n	100:0	>90:<10	-
71	H	H	H	H	CO ₂ Me	Arg(Pbf)	Aca	PEG	0.1/0.4	1.2	rt	o/n	100:0	>95:<5	-
70	H	H	H	CO ₂ Me	H	Ala	Aca	PEG	0.2/0.8	10	40	o/n	100:0	66:21:13	-
69	H	H	CO ₂ Me	H	H	Ala	Aca	PEG	0.2/0.8	3	60	o/n	100:0	22:44:33	-
68	H	H	CO ₂ Me	H	H	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	58:42	8:73:19	-
67	H	H	H	CO ₂ Me	H	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>95:<5	R=Me (70)
66	H	H	H	CO ₂ H	CO ₂ H	Arg(Pbf)	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>90:<10	R=Me (88)
65	H	H	H	CO ₂ H	Ala	Aca	PEG	0.1/0.4	1.5	rt	o/n	100:0	>95:<5	>90:<10	-
64	Me	H	H	H	CH ₂ NMe ₂	Ala	Aca	Wang	0.2/0.8	10	60	o/n	100:0	>90:<10	R=Me R=H R=H (>90)
63	Me	H	H	H	CH ₂ NMe ₂	-	Phe	Wang	0.2/0.8	10	60	o/n	100:0	>95:<5	R=Me R=H R=H (>90)
62	H	H	H	H	CH ₂ NMe ₂	Arg(Pbf)	Aca	Wang	0.2/0.8	5	60	o/n	100:0	>95:<5	R=Me R=H R=H (>90)
61	H	H	H	H	CH ₂ NMe ₂	Ala	Aca	Wang	0.1/0.4	2	rt	o/n	100:0	94:6	R=H R=H (>90)
60	H	H	H	H	CH ₂ NMe ₂	-	Phe	Wang	0.1/0.4	2	rt	o/n	100:0	>95:<5	R=H (>90)

a) product:starting material ratio of PEG linked dienes, or Wang cleaved dienes determined by integration of ¹H NMR alkene region

b) isomer ratio of PEG linked dienes, or Wang cleaved dienes determined by integration of ¹H NMR alkene region;

if 2 numbers given = 2E,4E;all other isomers; if 3 numbers given = 2E,4E,2E,4Z;all other isomers

c) for PEG and Phe-Wang cleaved dienes, isolated yields are given; for Aca-Wang linked dienes isolated quantities are too small for useful yield


d) R⁴ = CH₂NH₂

181-066 (E10)2PO-CH2CO-NH-Ala-Gly-PEG-OC


H3

expi pulse sequence: e2pul

SAMPLE		DEC. & UT	
date	Sep 5 96 dn	H1	
solvent	CDC13 def	0	
file	exp da	ann	
ACQUISITION		dmw	c
sfrq	499.843 dmf	200	
tn	H1 dpur	30	
at	2.002	PROCESSING	
np	25824 lb	not used	
su	6250.0 utfile		
fb	3500 proc	ft	
bs	4 fn	not used	
tpur	58 math	f	
pw	9.0		
d1	0 werr		
tof	0 wexp		
nt	500 wbs		
ct	401 unt	wft	
alock	n	DISPLAY	
gain	not used	sp	-82.7
FLAGS		wp	3986.6
il	n va	40817	
in	n sc	0	
dp	v wc	250	
hs	nn hzmm	15.95	
	is	31916.13	
	rfl	4258.6	
	rip	3628.9	
	th	154	
	ins	100.000	
	nm cdc ph		





COMPOUND 7



181-114 (E) 2PO-CH2-CH=CH-CONH-A-G-PEG

expl pul sequence: s2pul


SAMPLE DEC. & UT
 date Sep 28 96 dn HI
 solvent CDCl3 def 0
 file exp da nnn
 ACQUISITION dau c
 sfrq 499.843 dmf 200
 tn HI dpur 30
 at 2.002 PROCESSING
 np 29632 utfile
 su 7400.6 proc ft
 fb 4100 fn not used
 ba 4 math f
 tpur 50
 pu 9.0 uerr
 dl 0 uexp
 tof 0 uhs
 nt 500 unt wft
 ct 500 DISPLAY
 alock n sp -75.2
 gain not used up 3993.7
 FLAGS vs 43009
 il n ac 0
 in n uc 250
 dp y hzmm 15.97
 ha na is 45312.21
 rif 4838.8
 rfp 3633.9
 th 163
 ina 100.000
 nm cdc ph



COMPOUND 9

expt pulse sequence: s2pul



SAMPLE		DEC. & UT	
date	Nov 7 96	da	H1
solvent	CDCl3	def	0
file	exp	da	nan
ACQUISITION		das	c
sfrq	499.843	daf	200
tn	H1	dpur	30
at	2.002	PROCESSING	
np	25024	utfile	
sw	6250.0	proc	ft
fb	3500	fn	not used
bs	4	nath	f
tpur	56		
pw	9.5	werr	
dl	0	wexp	
tof	0	ubs	
nt	500	unt	uft
ct	203	DISPLAY	
alock	n	sp	-36.2
gain	25	up	5180.8
FLAGS		va	46069
il	n	sc	0
in	n	uc	250
dp	y	hzam	20.64
hs	na	is	14346.49
		rfl	629.2
		rip	0
		th	157
		ins	100.000
		nm	cdc: ph



194-36A Br-CH=CH-CONH-Ala-Aca-PEG

expt pulse sequence: s2pul

SAMPLE		DEC. & UT	
date	Dec 4 96	dn	H1
solvent	CDCl3	dof	0
file	exp	dm	nan
ACQUISITION		dm	
sfrq	499.843	daf	200
tn	H1	dpr	30
at	2.002	PROCESSING	
np	25024	utfile	ft
sw	6250.0	proc	not used
fb	3500	fa	not used
bs	4	math	f
tpur	56		
pw	9.5	werr	
dl	0	wexp	
tof	0	ubs	
nt	500	wnt	uft
ct	500	DISPLAY	
alock	n	ap	-38.1
gain	not used	up	4911.0
FLAGS		vs	43968
il	n	ac	0
in	n	uc	250
dp	y	hzm	19.64
ha	na	is	52416.93
		rfl	629.8
		rip	0
		th	105
		ins	100.000
		nm	cdc ph





COMPOUND 14
 $R^1 = H$, $Xaa_2 - Xaa_1 = Ala - Aca$

194-133 Br-CH=C(Me)-CONH-Ala-Aca-PEG


expt pulse sequence: a2pul

SAMPLE		DEC. & UT	
date	Jan 21 97	dn	H1
solvent	CDCl3	dof	0
file	exp	dm	nan
ACQUISITION		dwn	c
sirg	499.843	daf	200
tn	H1	dpur	30
at	2.002	PROCESSING	
np	25024	utfile	ft
sw	6250.0	proc	not used
fb	3500	in	f
ba	4	math	
tpur	56		
pw	9.5	uerr	
dl	0	uexp	
tof	0	uba	
nt	500	unt	uft
ct	136	DISPLAY	
aleck	n	sp	-45.7
gain	not used	up	4460.0
FLAGS		va	41364
il	n	ac	0
in	n	uc	250
dp	y	hzmm	27.84
ha	nn	is	26726.66
		rfl	329.3
		rip	0
		th	161
		ina	100.000
		nm	cdc ph



expl pulse sequence: s2pul

SAMPLE		DEC. & UT	
date	Jan 21 97	dn	H1
solvent	CDCl3	dof	0
file	exp	da	nan
ACQUISITION		das	c
afreq	499.843	daf	200
in	H1	dpur	30
at	2.002	PROCESSING	
np	25024	utfile	
sw	6250.0	proc	ft
fb	3500	fn	not used
bs	4	math	f
tpur	56		
pw	9.5	werr	
dl	0	wexp	
tof	0	uba	
nt	500	unt	uft
ct	204	DISPLAY	
aleck	n	sp	-64.4
gain	not used	up	4496.3
FLAGS		va	32943
il	n	sc	0
in	n	uc	250
dp	y	hzmm	17.99
hs	na	is	12294.10
		rfl	629.8
		rip	0
		th	148
		ins	100.000
	na	cdc	ph



COMPOUND 15
Xaa₂Xaa₁ = Ala-Aca